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IDENTIFYING MOLECULAR TARGETS AND VALIDATING NOVEL THERAPIES
FOR OVARIAN CANCER
Alejandro Villar-Prados, B.S.
Advisory Professor: Anil K. Sood, M.D.
Re-purposing of targeted therapies for additional tumor types is a promising avenue for
expanding treatment options for cancer patients, however accurately predicting what
re-purposed targeted therapy will be effective remains challenging. To address this
need, we developed a Therapy Predicting Tool (TPT) that accurately predicts the
beneficial therapeutic effect of clinically relevant targeted therapies and the
downstream pathways they may impact in the cancer of interest. Using ovarian cancer
as a model to biologically validate our tool, we determined that Bromodomain and
Extra-Terminal motif inhibitors (BETis), which target proteins such as BRD4, held the
greatest promise to produce therapeutic effects and impact relevant oncogenic gene
targets, such as Notch3, in this disease. In our pre-clinical models, we demonstrated
that BETis produce therapeutic effects and prolong survival. Furthermore, we
discovered that BRD4 directly regulates Notch3 transcription and its downstream
targets in ovarian cancer. Our findings provide a basis for further exploration and
application of our tool to identify and re-purpose targeted therapies for specific tumor
types.
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CHAPTER I

INTRODUCTION:
RATIONAL RE-PURPOSING OF TARGETED CANCER THERAPIES

1

Targeted Therapies in Cancer

The innumerable advancements in understanding the complex molecular
mechanisms that drive cancer initiation and progression in recent decades have paved
the way for the development of targeted molecular therapies (1, 2). The success of
targeted therapies rests on the principle of designing either small molecules or
antibodies that inhibit a biological process preferentially altered in a specific cancer
type (1, 2). By taking this approach, researchers and clinicians alike strive for precise
treatment of specific cancers that improve patient outcomes while minimizing the
cytotoxic effects that are inherent to standard chemotherapy treatments (1, 2). The
potential of targeted therapies has gathered the attention of a multitude of
pharmaceutical companies invest billions of dollars to further develop and test
promising targeted therapies and make them accessible to cancer patients (3, 4).
The design of targeted cancer therapies is aimed at inhibiting key molecules
involved in tumor intrinsic and/or extrinsic biologic processes that promote tumor
growth and progression. An example of a targeted therapy that attacks tumor intrinsic
cellular processes comes in the form of the recently U.S. Food and Drug Administration
(FDA) approved poly ADP-ribose polymerase (PARP) inhibitor (PARPi), olaparib (5).
PARP enzymes are involved in the repair of single strand DNA breaks (SSDB) and are
part of the base excision repair (BER) machinery (6). When PARP enzymes detect a
SSDB, they can bind directly to that region of DNA, begin adding ADP-ribose sugar
chains onto itself, which serves to signal for the recruitment of DNA ligase III, DNA
polymerase  and X-ray cross-complementing gene 1 (XRCC1) protein to fully repair
the segment of DNA (6). Excitement over the use of PARPi came after the observation
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that when PARPis are used in cells deficient in BRCA1 and 2 proteins, which are
needed for homologous recombination (HR) to repair double strand DNA breaks, it
produces synthetic lethality (7). In the context of cancer, loss of function of BRCA1 or 2
results in increased genomic instability, which is a hallmark of the disease (5, 6, 8).
Indeed, patients who have germline mutations in either BRCA1 or 2 have a significantly
higher risk of developing breast and ovarian cancers (9). However, treating BRCA1/2
deficient cells with PARPis, deprives them of alternative pathways for DNA repair,
resulting in accumulating genotoxic stress and lead to cell death (5, 6). This
understanding of the basic biology of DNA repair mechanisms prompted further
investigation of PARPi in patients with germline BRCA1/2 mutations (10). In 2014,
olaparib was FDA approved for the treatment of patients with ovarian cancer with
germline mutations in BRCA1/2 (5, 9, 10).
As mentioned above, targeted therapies have also been developed to target the
tumor micro-environment, the non-cancer cells and proteins that nourish the growth of
cancer cells (8). The microenvironment of the tumor is comprised of fibroblasts,
infiltrating immune cells, extracellular matrix, and new blood vessels (11). As with any
other tissue in our body, solid tumors need a supply of oxygenated blood in order to
grow and thrive (11). To achieve this, tumors promote the generation of new blood
vessels, or angiogenesis, by secreting vascular endothelial growth factor (VEGF) (11).
VEGF is a

potent inducer of endothelial cell proliferation and migration, which is

necessary for the formation of new blood vessels (12). By secreting VEGF, cancer cells
recruit endothelial cells to the micro-environment, inducing the formation of new blood
vessels (11). Researchers recognized this opportunity for targeted therapy and
developed bevacizumab, an IgG antibody that directly binds and sequesters secreted
VEGF. Bevacizumab quenches this effect by binding directly to VEGF, preventing it
3

from interacting with the vascular endothelial growth factor receptors 1 and 2
(VEGFR1/2) present in the surface of endothelial cells (11, 12). Preclinical studies
demonstrated promising anti-tumor effects in various solid tumors, which has led to the
use of bevacizumab in cancer patients, such as those with metastatic colorectal or
ovarian cancer (9, 12).
Despite the promise of the targeted therapies described above, due to the
natural genomic heterogeneity of cancer, most tumors evolve ways to acquire
resistance to these therapies, resulting in only modest improvements in patient
outcomes (2). Multiple reports have been published related to potential mechanisms by
which ovarian cancer cells can acquire resistance to PARPi, including developing
secondary mutations in BRCA1 and BRCA2 genes which can restore their function (5,
13, 14). In the case of bevacizumab, reports by our group have shown that resistance
to bevacizumab in ovarian cancer can be achieved by both tumor intrinsic and extrinsic
mechanisms (15, 16). In the wake of this challenge, various active areas of research
have risen to mitigate this problem, such as understanding the molecular mechanisms
of resistance to targeted therapies in order to overcome them and identifying novel
biomarkers in order to develop new targeted therapies. Unfortunately, these
approaches can be both time consuming and resource intensive (1, 2). Thus, a third
area of research has emerged to maximize the use of already developed and clinically
tested targeted therapies, or re-purposing targeted cancer therapies (17).
The re-purposing of targeted therapies has gain momentum in the past years
because it is cost effective and allows for quick expansion of therapeutic options
clinicians can have at their disposal to treat a cancer patients by diminishing the time
needed for pre-clinical testing (1). A limitation of this approach resides in the ability to
accurately predict which re-purposed targeted therapy will yield the best result in the
4

cancer of interest. Thus, researchers have turned to bioinformatics in order to
systematically and accurately predict what re-purposed therapies will produce the best
patient outcomes.

Role of Bioinformatics in Re-purposing Targeted Therapies and the Therapy
Predicting Tool
Accurately determining which re-purposed therapy will have the greatest impact
in the cancer of interest remains challenging, which researchers are trying to address
using bioinformatics. The unprecedented advancements in next generation sequencing
and array technologies have propelled a new era of bioinformatics. Thanks to this,
researchers have been able to generate and centralize massive amounts of expression
and gene mutation data on publicly available databases. Some of these databases
include The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression project
(GTEx) for assessing normal tissue gene expression, cBioPortal for cancer genomics,
the Gene Expression Omnibus (GEO) as well as the Broad Institute’s Cancer Cell Line
Encyclopedia (CCLE), Connectivity Map (CMAP) and Cancer Therapeutics Response
Portal (18-23). Researchers and bioinformaticians alike are working side by side to
develop computational algorithms for mining these databases. The intent is to rationally
identify, based on the mutational status of a tumor, the best therapeutic strategy to treat
cancers and produce better outcomes (24). The aim of generating such methods is to
quickly stratify patients according to their tumor genomic landscape, personalize their
treatment regimen, reduce the amount of side effects by smarter treatment options and
ultimately extend survival (17, 24). Furthermore, by employing strategies for the repurposing of targeted therapies, clinicians can rapidly increase treatment options to
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cancer patients and reducing the extended time and cost required for new drug
development.
There are still a set of challenges related to the effective use of computational
databases listed above. Each of these databases has an enormous breadth of
information, but discriminating between biological relevance and artifacts can be
difficult. This difficulty is enhanced when trying to create computational models that
incorporate information from several databases. Another challenge is biological
validation for these computational models (17). By nature, cancer is an extremely
heterogeneous and complex disease; thus, even if a promising gene signature is
identified that can lead to the use of a specific therapy, this does not mean that
targeting the genes or pathways in the gene signature will produce a positive biological
effect (17).
The limitations described above, of course, has not deterred researchers from
developing computational algorithms that can accurately identify potential targeted
therapies that can benefit patients with specific tumor types (24-27). In a recent study
by San Lucas et al., the group developed an in silico tool that uses TCGA, CMAP and
CCLE data sets to identify and match cancer gene signatures with cell lines harboring
similar alterations and test whether specific drug candidates are effective (25). The
authors were able to provide some biological validation by using cancer cell lines, but
did not perform any in vivo validation, nor did the group incorporate databases such as
GTEx to compare expression differences between cancer and normal tissues.
Incorporation of GTEx would allow for better accuracy for relevant gene targets
because it provides baseline expression levels of that gene. In another recent
publication by Jianting Sheng et al., the author created a similar tool but it can also
predict drug sensitivity signatures based on the genomic landscape of the cancer cells
6

of interest and identify candidate compounds (26). This approach, although promising,
also lacked extensive biological validation to confirm the accuracy of the computational
algorithm.
To build upon the concept of accurately and systematically identifying and repurposing targeted cancer therapies that will have positive patient outcomes, we
developed a novel Therapy Predicting Tool (TPT). The principal purpose of the TPT is
to determine which currently available targeted therapies that are in phase I clinical
trials can be re-purposed for other tumor types to improve patient outcomes (Figure 11). Our algorithm incorporates gene and protein expression data from various
databases, such as TCGA and GTEx, to simultaneously detect genes that have high
expression in various cancer types in comparison to their normal organ counterparts,
the impact of this high expression on patient survival, and specific drugs in phase I
development that are available to target those genes (Figure 1-1). Furthermore, the
TPT identifies potential functional relationships using tumor mRNA sequencing and
reverse phase protein array (RPPA) data by comparing expression of the target gene
queried with that of other upregulated genes in the cancer types of interest. This
expression data is further complemented by associating gene alterations of a specific
cancer with those of normal tissues by using both copy number and protein expression
data. The TPT thus allows easy and rational search for potential drug candidates for
specific tumor types. Based on our tool’s premise, we sought to validate the accuracy
of our tool using ovarian cancer as tumor model and carry out extensive biological
validation in both in vitro and in vivo pre-clinical models.
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Figure -1-1. Therapy Predicting Tool correlation of targeted therapy pairing with
altered gene expression in specific tumor types.
A screenshot example of one of the data outputs provided by the TPT. On the y-axis
are a few cancer types matched to a variety of gene targets which have high
expression in tumors, matched with currently available phase I clinical trial targeted
therapy. Green squares represent a significant association between the expression of
genes and its impact on patient survival and. The red square is a pop up window which
provides specific information about the cancer chosen, the gene of interest, targeted
therapy with mechanism of action and effect on overall survival by targeting that gene.
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CHAPTER II

INTRODUCTION:
The Potential Role of Bromodomain and Extra-Terminal motif inhibitors and
Notch3 Signaling in Ovarian Cancer

9

Ovarian Cancer

To proceed and begin validation of our TPT, we focused on ovarian cancer as a
disease model. Ovarian cancer is the deadliest gynecologic disease in women today
(9, 28). In the United States alone, there is an incidence of roughly 22,280 cases and
14,240 women are expected to die every year of the disease (28). Ovarian cancer
serves as an umbrella term since there exists a plethora of subtypes within the disease
due to the various cell types that make up the normal ovary (9, 29). These different cell
types have different developmental origins (29). The germ cells are derived from
endoderm that migrates to the gonadal ridge, giving rise to the future oocytes (29).
Interstitial cells are responsible for the secretion of hormones such as estrogen and
epithelial cells (29). Surface epithelial cells are derived from the Mullerian ducts and
cover the surface of the ovary (29). Each of these cell types can give rise to distinct
types of ovarian cancer, such as cancers of epithelial cell origin, germ cell derived
tumors and stromal sex-chord tumors (29). The most prevalent of these tumors are the
cancers of epithelial origin which are further divided into different subtypes, including
high

grade

serous,

low

grade

serous,

clear

cell

carcinoma,

endometrioid

adenocarcinoma and mucinous carcinoma (9, 29). For the remainder of this work,
including the analysis done by the TPT, when referring to ovarian cancer, I will be
referring to epithelial subtypes. Each one of these epithelial derived cancers have
distinct histopathological and molecular characteristics which dictate disease
progression, treatment options and survival (9). From the epithelial subtypes, high
grade serous ovarian cancer (HGSC) has the highest incidence in women (9). HGSC is
characterized for displaying an elevated degree of genomic instability and is thought to
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originate from the epithelial cells found in the fallopian epithelium of the uterine horn
known as serous tubal intraepithelial carcinoma (STIC) (30, 31). Patients with HGSC
are typically diagnosed at later stages of the disease and display dissemination of
tumor nodules throughout the peritoneal cavity (29). Furthermore, despite initial positive
response to chemotherapy agents in patients with HGSC, it has a high probability of
recurrence (28).
For most of the ovarian cancer types described above, including HGSC, the
main therapy modality is cytoreductive surgery (9). The goal of surgery is to remove as
much tumor as possible, which correlates with better survival outcomes (9, 32).
Following surgery, most patients receive adjuvant therapy with platinum and taxol
based chemotherapy (9). As described above, despite the use of the modalities,
patients with advanced HGSC have a recurrence rate (approximately 80%) (9). Faced
with this reality, clinicians and basic researchers alike are exploring ways not only to
maximize current treatment modalities of the disease but to also identify novel
therapeutics. As described in Chapter I, one attractive avenue to expand treatment
options for ovarian cancer patients is the incorporation of molecular targeted therapies
such as bevacizumab and PARPi (9). The use of both of these therapies has shown to
increase patient survival (9). However, much like many other tumor types and despite
promising results, ovarian cancer inevitably develops resistance mechanisms to these
targeted therapies (15, 16, 33). Thus, it has become imperative to investigate
methodologies that can rapidly identify clinically ready therapies that can be repurposed and quickly expand therapeutic options for ovarian cancer patients.

Identifying the Bromodomain and Extraterminal Domain protein BRD4 as a
Therapeutic Avenue for Ovarian Cancer

11

To identify novel therapeutics for ovarian cancer patients, we turned to our TPT.
Our analysis revealed that for ovarian cancer, our top candidate targeted therapies to
be re-purposed were the epigenetic small molecule inhibitors known as bromodomain
and extra terminal domain Inhibitors (BETis). BETis are a class of inhibitors which
target the BET family of proteins, including BRDT (only expressed in testis), BRD2,
BRD3 and BRD4 (34-36). BET proteins are widely regarded as epigenetic readers and
act as molecular scaffolds that recruit various components of the gene transcription
machinery (36). The BET proteins achieve this due to the presence of functional
domains called bromodomains (36). These functional domains allow BET proteins to
bind directly to acetylated histones, which are markers of transcriptionally active genes,
at either gene promoters and/or enhancers regions (Figure 2-1A) (34, 36). BETs can
recruit factors such as the mediator complex at enhancer sequences or positive
transcription elongation factor b (PTEF-b) at gene promoters to facilitate the
transcription of the target gene (35-39) (Figure 2-1A). It is also important to note that
BET proteins can also be recruited to gene promoters independently of their binding to
acetylated histones by directly interacting with other cell transcription factors, potentially
independent of its bromodomains (38). BETis bind to the bromodomain of BET proteins
and block the ability of BET proteins to interact with acetylated chromatin, resulting in a
decrease in gene transcription (Figure 2-1B) (35).
Out of the BET proteins, one that has gathered much attention in the past 4 to 5
years is the bromodomain containing protein 4 (BRD4). BRD4 is over-expressed in a
wide range of cancers and is known to be a key regulator of cell cycle progression by
regulating expression of genes necessary for G1/S phase and G2/M phase transition
(39-42). The prominent role of BRD4 in cancer growth and progression came after
initial studies with the BETi JQ1 (35, 43, 44).
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Figure 2-1. Mechanism of BRD4 (BET protein) mediated transcription and how
BETis interfere with their function. (A) Recruitment of BRD4 to either gene superenhancer or promoter regions by binding to acetylated chromatin. Upon binding, it can
recruit protein complexes such as Mediator or P-TEGFb to promote RNA polymerase II
(RNA Pol. II) activation. (B) Mechanism of action of BETis by which the inhibitors bind
to the bromodomains of BRD4 and block its ability to interact with acetylated chromatin.
Figure adapted from Panagis Filippakopoulos and Stefan Knapp, Nature Reviews:
Drug Discovery, 2014 (35).
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Using this drug, pioneer studies conducted by Filippakopoulos P. et al., Delmore et al.
and Mertz J.A. et al. observed that JQ1 was not only able to produce anti-growth
effects in these models but it was also able to downregulate the oncogene MYC using
multiple myeloma and acute myelogenous leukemia tumor models (43-45). These
findings opened the avenue of using epigenetic targeted therapies to indirectly
downregulate expression of key oncogenes which were proven difficult to directly target
in the past (34). Following this initiative, various groups have identified additional gene
targets downstream targets of BRD4 in various cancer and non-cancer models (46-53).
Another tumor model in which the inhibition of BRD4 using BETis has produced
promising results is in midline NUT carcinoma (54, 55). This rare cancer is
characterized by growth of malignant and undifferentiated squamous epithelial cells
that invades midline structures (54). The molecular mechanism that gives rise to these
tumors is due to the creation of fusion proteins that arise from chromosomal rearrangements (54). The most commonly observed fusion is of the NUT gene with
BRD4 that results in constitutive expression of BRD4 in these cells (54). This
overexpression of BRD4 pushes the cancer cells to persist in an undifferentiated state
(54). Treatment of these tumors with BETis promotes the cancer cells to differentiate
and inhibits their growing (54). Due to these observations described here and in
leukemia models, the interest in further studying the roles of BRD4 and the use of
BETis in cancer has grown exponentially (34). Furthermore, research is also pointing to
the use BETis outside of cancer to treat diseases where acute and chronic
inflammation is present (35). It is thanks to these research advancements that the
multiple BETis are currently being tested in clinical trials (34).
In ovarian cancer, our TPT predicted that the use BETis would provide a
beneficial survival effect in ovarian cancer patients. To further investigate the
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oncogenic role of BRD4 in ovarian and externally validate our TPT predictions, we used
the GTEx and TCGA databases (outside of the TPT) to confirm the expression of
BRD4 compared to normal ovary tissue and how it correlates with patient survival
(Figure 2-2). Our results show that BRD4 is over-expressed in ovarian cancer when
compared to normal ovarian tissue using the GTEx database. Furthermore, TCGA
analysis revealed that patients with higher tumor levels of BRD4 also have a worse
survival rate (Figure 2-2B, p < 0.02). Taken together, these bioinformatics findings set
the base for further explore the role of BRD4 and the therapeutic use of BETis in
ovarian cancer patients.
Role of Notch3 Signaling in Ovarian Cancer
In our initial analysis, we observed that BRD4 overexpression strongly correlated
with Notch3 upregulation in ovarian cancer (Figure 2-3). This observation was
particularly interesting given the pro-tumorigenic effect of Notch3 over-expression in
ovarian cancer (56-59). The Notch3 receptor belongs to the Notch family of
transmembrane receptors and ligands (60). In mammals, there are a total of four Notch
receptors and five transmembrane Notch ligands (61). Notch signaling activation
follows an elegant sequence of downstream molecular events (Figure 2-4). Upon
interaction with its ligand, the Notch receptors undergo a series of proteolytic cleavages
by the -secretase complex (GS) located on the cell plasma membrane, resulting in the
release of the Notch intracellular domain (NICD) (Figure 2-4) (61). The NICD is then
translocated to the cell nucleus where it can form a complex with the DNA binding
protein RBPJκ (61).

15

Figure 2-2. BRD4 is over-expressed in ovarian cancer and correlates with
significantly worse patient survival. (A) GTEx results comparing expression of BRD4
mRNA as transcripts per million (TPM) in normal ovarian tissue (blue rectangle)
compared to ovarian carcinoma (red rectangle). (B) Survival plot of ovarian cancer
patients with high BRD4 mRNA expression (red line) versus low expression (blue line).
Statistical analysis was done by running the log-rank test in the R “survival” package.
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Figure 2-3. BRD4 expression highly correlates with Notch3 over-expression in
ovarian cancer. Heat map comparison of BRD4 mRNA levels with the expression
levels of proteins gathered from reverse phase protein array (RPPA) form molecular
pathways that are frequently altered in ovarian cancer. A spearman Rho less than zero
means the two genes have an inverse correlation (high BRD4 correlates with
decreased expression of that gene), and a Spearman Rho of greater than zero
indicates that BRD4 expression is positively correlated with the specific gene.
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Figure 2-4. Molecular overview of Notch signaling. Interaction of the Notch ligand
with the Notch receptor induces a series of proteolytic changes on the receptor that
results in the release of the Notch intracellular domain (NICD). The NICD is then
translocated to the cell nucleus. In the nucleus, it can directly bind to RBPJ. RBPJ is
constitutively bound to genomic loci that correspond to Notch target genes where it is
bound to transcriptional co-repressors (Co-rep). When the NICD binds to RBPJ, the
NICD displaces the Co-rep and recruits transcriptional co-activators (Co-act). This then
allows for the active transcription of Notch downstream target genes. Figure adapted
and modified from Kopan and Ilagan, Cell Reviews, 2009 (61).
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The NICD/RBPJκ complex recruits additional transcriptional co-activator proteins such
as mastermind like-1 (MAM1), a histone acetyltransferase, inducing expression of
target either at gene promoter or enhancer regions (60, 61). Common Notch signaling
target genes include the Hes and Hey family of transcription factors, which in turn
regulates the transcription of other genes (61). Interestingly, downstream targets of
Notch signaling can be tissue and context dependent, which can result in the
transcription of distinct downstream gene (60, 62, 63). This demonstrates how the
singular activation of a Notch receptor, can have broad implications on the cells
transcriptional network.
Notch3 signaling, as with all of the other Notch receptors, has been attributed to
a plethora of biological processes both in normal development and in disease (60, 64,
65). In the context of development, Notch3 expression plays a significant role in the
development of the mammalian arterial vascular system and in adults is mostly
expression in arterial smooth muscle cells (66, 67). This is further evidenced by mouse
genetic studies whereby Notch3 whole body knockout produces incomplete
differentiation of arterial vessels (66). In the setting of disease, Notch3 over-expression
have been implicated to play a role in the development of vascular pathologies such as
pulmonary arterial hypertension, as well as cancers including ovarian cancer (57, 65,
68-73).
In ovarian cancer, Notch3 is commonly over-expressed, partly due to gene copy
number amplification at its genomic locus in human chromosome 19 (57, 74). Notch3
over-expression in ovarian cancer is associated with increased chemo-resistance,
recurrence in treated patients and with worse overall patient survival (57, 58, 74, 75).
Strategies to directly target and downregulate Notch3 signaling in ovarian cancer
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remain challenging. One avenue to inhibit Notch3 signaling is to inhibit -secretase, a
class of inhibitors known as -secretase inhibitors (GSi) (76). GSis inhibit the

-

secretase protein complex, which is responsible of cleaving the Notch receptors upon
activation (Figure 2-4) (60). This impedes the release of the NICD and its translocation
to the nucleus (60, 76). In pre-clinical models, the use of GSis can sensitize Notch3overexpressing cells to cisplatin (77). Despite these findings, the use -secretase
inhibitors have not been effective in the clinic owing to their toxic side effects (76).
The TPT demonstrated that BRD4 over-expression highly correlates with Notch3
upregulation in ovarian cancer. Interestingly, both BRD4 and NOTCH3 are located on
the short arm of chromosome 19, a locus that is frequently amplified in ovarian cancer
(78). There is a similar genomic geographical relationship between the rest of the
mammalian Notch receptors and the BET proteins: BRD2 is adjacent to NOTCH4 on
chromosome 6, BRDT is adjacent to NOTCH2 on chromosome 1 and BRD3 is adjacent
to NOTCH1 chromosome 9 (41). This observation has led to the hypothesis of a
functional relationship between these gene families (41). BRD4’s ability to be a
transcriptional activator and regulating the expression oncogenes such as MYC in other
tumor models raises the possibility of utilizing BETis to inhibit Notch3 signaling in
ovarian cancer (43). This is especially attractive from a clinical point of view because
BETis are better tolerated by patients than GSis (34, 76). This provides further rationale
to biologically validate our TPT and test the main hypothesis that the use BETis are a
beneficial therapeutic avenue in ovarian cancer by targeting the Notch3 pathway.
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CHAPTER III

MATERIALS AND METHODS AND RESULTS:
BIOLOGICAL VALIDATION OF THE TPT AND EXPLORING THE FUNCTIONAL
RELATIONSHIP BETWEEN BRD4 AND NOTCH3 IN OVARIAN CANCER
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MATERIALS AND METHODS:

Development of the Therapy Predicting Tool
To predict novel indications for targeted therapeutics, we applied an integrated
visualization interface using publicly available TCGA and GTEx data. The tool contains
the following main components: (i) Survival analysis from Kaplan-Meier was performed
using log-rank p-values and median overall and progression-free survival times to
compare sample sets with low and high protein expression in the tumor. The low and
high groups are defined using the median expression level, or the lowest and highest
quartiles. (ii) Tumor mRNA expression levels are analyzed using a heat map showing
median-centered median expression levels. (iii) Association of targets with copy
number gain or loss in the tumor is analyzed in a manner similar to that of mRNA
expression. (iv) Normal-tissue expression levels, which can also help identify ideal
cancer-specific targets, are examined using a heat map similar to that for tumor mRNA
expression.
The TPT also includes large-scale correlation calculations (Spearman rank
correlation coefficients) to provide information and insight on possible associations with
protein expression and phosphorylation. Furthermore, using TCGA copy number and
gene expression data, the TPT determines which copy number changes are associated
with significant alterations in gene expressions.

Reagents and antibodies
For in vitro experiments, we used the BETi CPI203, purchased from SigmaAldrich (#SML1212), and the BETi CN210, kindly provided by ConverGene. The
inhibitors were re-suspended in dimethyl sulfoxide (DMSO; #D2650; Sigma-Aldrich) to
make a working stock of 10 mM. DMSO diluted at 1:1,000 was used as the vehicle
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control for all in vitro experiments. For Western blots, we used the following antibodies:
Notch3 (#D11B8; Cell Signaling Technology; 1:1,000), Hes1 (#D6P2U; Cell Signaling
Technology; 1:700), BRD4 (#A700-004; Bethyl Laboratories; 1:5,000), and vinculin
(#V9131; Sigma-Aldrich; 1:10,000). For IHC analysis of paraffin sections, the following
antibodies were used: BRD4 (#A700-004; Bethyl Laboratories; 1:100), Notch3
(#ab23426; Abcam; 1:100), Ki67 (#RB-9043-P1; NeoMarkers, 1:200), and cleaved
caspase-3 (#9661S; Cell Signaling Technology; 1:100). For doxycycline induction of
shRNA in vitro, we treated cells with 100 ng/mL of doxycycline (#D9891; SigmaAldrich). For in vivo induction of BRD4 shRNA, mice harboring OVCAR 5 tumors were
placed on a daily 200 mg/kg doxycycline-chow diet (#14727450; Fisher Scientific).

Cell lines and tissue culture
The human ovarian cell lines used in this study were obtained from the
American Type Culture Collection (ATCC) and The University of Texas MD Anderson
Cancer Center Characterized Cell Line Core Facility, except for OVCAR 432, which
was kindly provided by Dr. Ronny Drapkin (Dana-Farber/Harvard Cancer Center). Cell
lines’ identities were validated via short tandem repeat DNA profiling carried out by the
Characterized Cell Line Core Facility. Routine mycoplasma testing was carried out
using the ATCC PCR Universal Mycoplasma Detection Kit (#30-1012K). The cell lines
OVCAR 3, OVCAR 432, A2780, HeyA8, and OVCAR 8 were cultured in HyClone
Roswell Park Memorial Institute 1640 medium (RPMI; #SH30027.01; GE Healthcare
Life Sciences) media supplemented with 15% fetal bovine serum (FBS) (Sigma-Aldrich)
and 0.2% gentamicin (#50146970, Fisher). OVCAR 4 cells were grown in RPMI
supplemented with 10% FBS and 0.2% gentamicin (#50146970, Fisher). The
generation and culture of OVCAR 4ip1 cells is described below. OVCAR 5 cells were
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cultured in Dulbecco Modified Eagle Medium (DMEM; #10-013-CV; Corning)
supplemented with 10% FBS and 0.2% gentamicin. All cells were grown in incubators
kept at 37°C with 5% CO2. For maintenance and passage of cultured cells, cells were
washed twice with 1× HyClone phosphate-buffered saline (PBS; #SH30256.01; GE
Healthcare Life Sciences) and trypsinized using 0.25% HyClone trypsin (#SH30042.01;
GE Healthcare Life Sciences). Cells expressing doxycycline-inducible shRNA
constructs were grown in complete media supplemented with Tet System Approved
FBS (#631107; Takara) to avoid induction of BRD4 shRNA expression in culture.

Cell siRNA transfections
All siRNA sequences (Table 3-1) were purchased from Sigma-Aldrich. Cells
were seeded in six-well plates at a density that yielded 50% confluency after 24 hours
of plating (150,000 to 200,000 cells/well). The next day, about 2.6 g (0.196 nmol) of
siRNA sequences against BRD4 (Table S1) was mixed at a 1:3 ratio with
Lipofectamine RNAiMAX (#13778500; Thermo Fisher Scientific) were prepared in
serum-free media for 30 minutes. Then, the transfection complex was added to cells
that had been washed twice with PBS and re-fed with serum-free media beforehand.
Cells were incubated with the siRNA/RNAiMAX complex for 6 hours in a 37C, 5% CO2
tissue culture incubator and re-fed with complete media after the 6 hour incubation.
Cells were then harvested for both qPCR and Western blot analysis to verify BRD4
knockdown.
For transfection in 96-well plates, cells were plated at a density of 7,000 to
10,000 cells per well in technical replicates of 10 wells per siRNA sequence used. The
next day, cells were transfected with siRNA in serum-free media and incubated for 6
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hours in the tissue culture incubator. Cells were then re-fed with complete media and
subjected to MTT viability assays.
MTT viability assays
Specified cell lines were seeded in 96-well plates at an initial density of 3,000
cells per well in quadruplicate technical replicates. Once cells were attached, after 24
hours, culture media were removed and replaced with 150 L of culture media with
escalating concentrations of CPI203 or CN210 (0.01, 0.1, 0.5, 1.0, 5, and 10 M). We
used DMSO (1:1000 dilution) as a vehicle control. After 72 hours of cell growth in the
tissue culture incubators, 50 L of 1.5 mg/mL MTT (#J19265; Affymetrix) solution was
added to each well of the 96-well plates and incubated for 2 hours in the tissue culture
incubator. Then, media with MTT reagent were discarded, and 100 L of DMSO was
added to each well, completely re-suspending the MTT byproduct metabolized
formazan. Plates were then analyzed using a plate spectrophotometer reader at an
absorbance of 540 nm. To calculate cell viability percentage, the mean absorbance
values for each treatment were normalized to DMSO vehicle–treated wells.

Colony formation assays
The indicated cell lines were plated in six-well plates in single-cell suspensions
at a density of 1,000 cells per well and in technical triplicates. Twenty-four hours after
seeding, cells were re-fed with fresh media containing either DMSO (1:1000 dilution) or
the specified BETi (CPI203 or CN210) at 1 M. Cells were left growing in a tissue
culture incubator for 7 to 10 days. Afterward, the cells were washed three times with
ice-cold PBS, fixed with ice-cold 100% methanol for 10 minutes. After 10 minutes, the
methanol was discarded and cells were stained with crystal violet solution (SigmaAldrich; 0.5% crystal violet with 20% methanol in Milli-Q water [EMD Millipore]) for 30
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minutes at room temperature with light agitation. Lastly, the crystal violet was
discarded, and the cells were washed with de-ionized Milli-Q water three times and left
to dry at room temperature overnight.

EdU incorporation assay and Annexin V staining
Cells were plated in technical duplicates per experiment in six-well plates at a
density of 50,000 cells per well. The next day, cells were treated with the specified
BETi or were transfected with siRNA. BETi-treated cells were harvested 72 hours after
treatment. siRNA-transfected cells were harvested 96 hours after transfection.
Harvested cells were then pulsed with EdU for 1.5 hours and processed using the
Click-iT Plus EdU Alexa Fluor 488 Flow Cytometry Assay Kit (#C10632; Thermo
Fisher) following the manufacturer’s protocol. For Annexin V staining, we used the BD
Biosciences FITC Annexin V Apoptosis Detection Kit I (#556547; BD Biosciences) and
followed the manufacturer’s protocol. For flow cytometry data collection and analysis,
we used the Beckman Coulter Gallios Flow Cytometer.

RNA extraction and qPCR analysis
Cells that were either treated with a BETi or transfected with siRNA were
washed with PBS and placed in TRIzol (Ambion TRIzol Reagent, #15596018; Thermo
Fisher Scientific). For RNA extraction and purification, the Direct-zol column kit (#11331; Genesee Scientific) was used following the manufacturer’s protocol (including the
DNase step). RNA was eluted with DNase- and RNase-free water, and the amount of
RNA was quantified with the NanoDrop 2000 (Thermo Scientific). Any RNA that was
not used immediately for reverse transcriptase reaction to create complementary DNA
(cDNA) was stored at –80C.
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For cDNA synthesis, 1 g of purified RNA was converted to cDNA using the
Verso cDNA Synthesis Kit (#AB1453/B; Thermo Fisher Scientific) following the
manufacturer’s protocol. If not used immediately, newly synthesized cDNA was stored
at –20C. For qPCR analysis, we used Power SYBR Green PCR Master Mix
(#4367659; Applied Biosystems) using the primers listed in Table S1 loaded in 96-well
plates (#AB-1100; Thermo Scientific) and ran samples using the Applied Biosystems
7500 Real-Time PCR System. Data analysis was done using Applied Biosystems 7500
software version 2.3 to determine relative CT quantification (fold change = 2-CT)
using RPLP0 (also known as 36B4) as a housekeeping gene. See primer sequences in
Table 3-1.

Western blot analysis
Cells treated with the indicated BETi or transfected with siRNA were harvested
and lysed with radioimmunoprecipitation assay buffer (RIPA) (25 mM Tris [pH 7.5], 150
mM NaCl, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 1% Triton X)
supplemented with, for each experiment, single-use phosphatase and protease
inhibitors (#78442; Thermo Scientific). Protein concentrations for lysed samples were
determined using the Micro BCA Protein Assay Kit (#23235; Thermo Fisher Scientific)
following the manufacturer’s protocol. For all Western blots, 30 g of total cell lysate
diluted with 2× Laemmli sample buffer (#1610737; Bio-Rad) was loaded in either 6% or
10% sodium dodecyl sulfate denaturing polyacrylamide gels. Protein was then
transferred to a nitrocellulose membrane, blocked with 5% non-fat dry milk (#AB1010901000; AmericanBio) in Tris-buffered saline (TBS)-T (0.1% Tween-20) for 1 hour at
room temperature, and incubated with the indicated antibodies diluted in 5% milk in
TBS-T overnight at 4°C with light agitation. The next day, the membrane was washed
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three times with TBS-T for 10 minutes with light agitation. After the last wash, the
membrane was incubated with species-specific secondary antibodies conjugated to
horseradish peroxidase (#NA931V and #NA934V; GE Healthcare), diluted 1:2,500 in
5% milk in TBS-T, for 1 hour at room temperature with light agitation. The membrane
was then washed three times in TBS-T and finally developed using Western Lightning
Plus ECL (#NEL105001EA; Perkin Elmer) on x-ray film (#F-BX57; Phenix). For reprobing of Western blots, we stripped membranes with Restore PLUS Western Blot
Stripping Buffer (#46430 Thermo Fisher Scientific), re-blocked them with 5% milk TBST, and incubated them with primary antibody.

Cloning of inducible shRNA constructs and lentiviral production
To generate and clone shBRD4 sequences into doxycycline-inducible lentiviral
expression vectors, we first designed the sequences on the basis of validated shRNA
sequences

from

the

Sigma-Aldrich

MISSION

shRNA

library

(Table

3-1).

Oligonucleotides (oligos) were cloned into a Tet-pLKO-puro lentiviral vector (plasmid
#21915;

Addgene)

in

accordance

with

Addgene’s

on-line

protocol

(https://www.addgene.org/tools/protocols/plko/). For oligo duplex annealing, 1 L of
each oligo (100 M) was combined with 1 L of 10× T4 ligase buffer (#B0202S; New
England Biolabs [NEB]), 1 L of T4 polynucleotide kinase (#M0201S; NEB), and 6 L
of water, and the reaction was incubated at 37°C for 30 minutes in a Master cycler
(Eppendorf). Next, the temperature was increased to 95C and decreased by 5°C
every 1 minute until reaching 25°C. The oligo duplex was then ligated to the Tet-pLKOpuro vector cut previously with BshTI (#FD1464; Thermo Fisher Scientific) using 2 L
of the newly formed oligo duplex, 3 L of gel-purified cut Tet-pLKO-puro vector, 1 L of
T7 ligase (#M0318S; NEB), 1 L of 2× T7 ligase buffer, and 3 L of nuclease-free
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water. The ligation was incubated at 25C for 1 hour. The ligation product was then
transformed in NEB Stable Competent Escherichia coli (#C3040I) following the NEB
protocol, plated on ampicillin plates, and grown at 30C for 16 hours. Colonies were
picked and grown in LB media (#12795027; Thermo Fisher Scientific) supplemented
with ampicillin (#BP1760-5; Fisher BioReagents). Plasmid DNA was purified using the
QIAGEN Plasmid Plus Midi Kit (#12945) following the manufacturer’s protocol and
sequenced in the MD Anderson Cancer Center Sequencing and Microarray Facility to
confirm the presence of the BRD4 shRNA sequence using the sequencing primer 5′
GGCAGGGATATTCACCATTATCGTTTCAGA.
For lentiviral production, HEK 293T cells (grown in DMEM, 10% FBS, and 0.2%
gentamicin) were transfected using Lipofectamine 2000 (#11668500; Thermo Fisher
Scientific) with 10 g of Tet-pLKO-puro plasmid containing either the shBRD4
sequence or the shControl non-targeting sequence (Table S1), along with 5 g of
psPAX2 (#12260; Addgene) and 2.5 g of pMD2.G (#12259; Addgene) lentiviral helper
plasmids. Supernatant containing newly generated virus was centrifuged to clear any
cell debris and syringe-filtered using a 0.45-m filter (#190-2545; Thermo Fisher
Scientific). For infection of OVCAR 5 cells, cells were plated at 50% confluency in sixwell plates, were incubated with 2 mL of newly produced virus along with polybrene at
a 1:1,000 dilution (#sc-134220; Santa Cruz Biotechnology) for 24 hours, and were then
re-fed using complete media. Lastly, cells were positively selected using puromycin
(#A11138-03; Gibco). Surviving cells were expanded and used for subsequent in vitro
and in vivo experiments.
For labeling cells with luciferase for IVIS imaging, cells were infected with the
lentiviral vector pGreenFire1-CMV (#TR011PA-1; System Biosciences), which co29

expresses green fluorescent protein, using the protocol described above. Cells were
then sorted at the MD Anderson Flow Cytometry and Cellular Imaging Core Facility for
green fluorescent protein positivity and used for subsequent in vivo experiments.

Immunohistochemistry analysis of tumor nodules
Harvested tumor nodules were embedded in paraffin blocks and sectioned by
the MD Anderson Research Histology, Pathology, and Imaging Core. Slides were deparaffinized as follows. First, slides were placed in 60C for 30 minutes. Next, we did
one incubation in 100% xylene (#C8H10, Fisher Chemical) for 4 minutes followed by
another xylene incubation for 3 minutes. Next were two incubations with 100% ethanol
for 2 minutes, two incubations with 95% ethanol for 2 minutes, one incubation in 80%
ethanol for 1 minute, and two final incubations in Milli-Q water for 5 minutes each. For
antigen retrieval to stain for Notch3 and cleaved caspase-3, slides were placed in a
vegetable steamer (Hamilton Beach) in sodium citrate (pH 6) buffer for 25 minutes. For
antigen retrieval for staining with Ki67, we used Diva Decloaker (#DV2004MX; Biocare
Medical) instead of sodium citrate. Endogenous tissue peroxidase activity was
quenched with 3% hydrogen peroxide in 100% methanol for 12 minutes. Slides were
then washed and blocked with 5% goat serum in PBS for 1 hour at room temperature
and we added primary antibody diluted in 5% goat serum in PBS overnight at 4C in a
humidified chamber. BRD4, Notch3, and cleaved caspase-3 were diluted at 1:100,
while Ki67 was diluted at 1:200. For Notch3, BRD4, and cleaved caspase-3, slides
were washed three times with PBS for 5-minute intervals and then incubated with
biotinylated anti-rabbit antibody (#GR602H; Biocare Medical) for 20 minutes at room
temperature. Then, slides were washed three times with PBS for 5 minutes at room
temperature and then incubated with a streptavidin horseradish peroxidase label
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(#HP604H; Biocare Medical) for 20 minutes at room temperature and washed three
times with PBS for 5 minutes at room temperature. For Ki67 IHC staining, we incubated
slides with secondary anti-rabbit antibody conjugated to horseradish peroxidase (#111036-047; Jackson ImmunoResearch) diluted in 5% goat serum in PBS at a 1:500
dilution for 1 hour at room temperature. After secondary antibody incubation, slides
were again washed with PBS and then briefly washed with PBS containing Brij 35
(#858366; Sigma-Aldrich) and placed in DAB (#750118; Thermo Fisher Scientific).
Upon color change, slides were rinsed in de-ionized Milli-Q water, counter-stained with
hematoxylin (#GHS316; Sigma-Aldrich) for 15 seconds, rinsed in water again, and left
to dry. When completely dry, slides were mounted with coverslips with permount
(#sp15-100; Fisher Scientific). Slides were imaged using the Leica DM4000 B LED
microscope. For quantification of cleaved caspase-3, Ki67, and BRD4 staining, five
random high-power field photos were taken, and stained cells were counted manually
using ImageJ software.

In vivo experiments
For all in vivo mouse experiments, female athymic (NCr-nude) mice were used,
purchased from Taconic Biosciences. Mice were taken care of in accordance with the
American Association for Assessment and Accreditation of Laboratory Animal Care and
the U.S. Public Health Service policy on Humane Care and Use of Laboratory Animals.
All studies and experiments carried out in this work were also supervised and approved
by the MD Anderson Institutional Animal Care and Use Committee. All mice used were
10 to 15 weeks old at the time of tumor intraperitoneal injection cell injections. For
OVCAR 5 cells, we injected 1 × 106 cells intraperitoneally per mouse. For OVCAR 4ip1
cells, we injected 2 × 106 cells per mouse. Tumor cells to be injected were first grown in
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the indicated media in tissue culture incubators until reaching 70% confluency. The
cells were then trypsinized, washed twice with PBS (to remove any residual trypsin)
and finally re-suspended in ice-cold Hank’s Balanced Salt Solution (#21-021-CV;
Cellgrow). For determining the presence of tumors, mice were injected with 200 L of
14.7 mg/mL luciferin (#LUCK-1G; Gold Bio) and imaged using the IVIS. Any non-tumor
bearing mice were removed from the experiment. After injection and confirmation of
tumor presence, mice were randomly assigned to the treatment groups described in
main text. During the course of all in vivo experiments, the primary investigator was not
blinded to the allocation of each treatment group, but at the time of tumor dissections,
all investigators involved were blinded to group allocations to determine the outcome of
the experiment.
For CPI203 experiments, 10 mice were initially calculated for each treatment
group since this sample size gave an 80% power to detect a 50% decrease in tumor
weights and nodules with a 95% confidence. Tumor cell take rates were not 100%, thus
the final mouse number per group are specified in the figure legends of each
experiment. Mice were treated daily with either 10 mg/kg CPI203 diluted in PBS or with
PBS alone, injected intraperitoneally. After 21 days of treatment, mice were euthanized,
and tumor nodule numbers and weights were recorded accordingly. Harvested nodules
were then placed in 10% buffered formalin phosphate (#SF100-4; Fisher Scientific) for
subsequent embedding in paraffin blocks for IHC staining. For tumor weights and
nodule analysis, we tested for and excluded outliers using the ROUT analysis provided
by Graph Pad Prism 7 software package to identify for multiple outliers present in each
treatment group (Q = 1%). One outlier was removed from CPI203 treated OVCAR 5
tumor bearing mice (Fig. 3C and Fig. S3A).
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For CN210 in vivo experiments, we re-suspended CN210 in 30% solution of
Kolliphor (#42966-1KG; Sigma-Aldrich) diluted in water and adjusted with 1.05
equivalent of 0.1 N HCl for dosing. Sonication was done to completely dissolve all
CN210. CN210 was delivered orally at 50, 100 or 200 mg/kg daily for 2 days to OVCAR
5 tumor-bearing mice, with n = 3 mice per group. Twenty-four hours after the final dose,
mice were euthanized and tumors were harvested for Notch3 IHC staining.
For survival experiments, luciferase-labeled OVCAR 5 cells expressing either
doxycycline-inducible shBRD4 or non-targeting shControl (described in supplementary
material) were grown in DMEM, 10% Tet System approved FBS, and 0.2% gentamicin
to 70% confluency and injected into the peritoneal cavities of mice. The mice were then
imaged 7 days later using IVIS imaging and, upon confirmation of tumor establishment,
were started on a 200 mg/kg doxycycline-chow diet. Mice were monitored daily, and
once they became moribund owing to disease burden, they were euthanized and
tumors were harvested for IHC staining.

Generation of OVCAR 4ip1 cells
OVCAR 4 parental cells were labeled with luciferase, as described above, and
injected (2 × 106) into the peritoneal cavities of nude athymic mice. Three weeks after
injection, tumor nodules were harvested, placed in sterile serum-free RPMI, and
processed in the laboratory under sterile conditions. Briefly, tumor cells were
dissociated using the gentle MACS dissociator (Miltenyi Biotec). Recovered tumor cells
were then cultured in RPMI with 10% FBS and 0.2% gentamicin. Cells were then
expanded and underwent short tandem repeat DNA fingerprinting analysis to confirm
the identity of OVCAR 4 cells and underwent mycoplasma testing before their injection
into mice
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Liposome nanoparticle preparation and delivery in vivo
In vivo delivery of siBRD4 2 was achieved by incorporating the siRNA in a
previously described DOPC liposomal particle delivery system (79). Briefly, DOPC and
siRNA were combined at a ratio of 1:10 (siRNA to DOPC) in the presence of excess
tertiary butanol. Tween-20 was then added to the mixture at a ratio of 1:10 (Tween-20
to DOPC/siRNA mixture). This combination was mixed in a vortexer, frozen in a bath of
acetone and dry ice, lyophilized, and kept at –20C until needed for in vivo injections.
For in vivo administration, the DOPC/siRNA mixture was hydrated in sterile PBS
without calcium or magnesium at room temperature to a concentration of 25 g/mL and
injected in doses of 200 L, for a total of 5 g per OVCAR 5 tumor-bearing mouse, in
the peritoneal cavities of mice twice a week. After three treatments, mice were
euthanized, and tumor nodules were harvested for IHC staining.

ChIP and ChIP PCR
For ChIP experiments, cells were plated in 15-cm tissue culture dishes and
grown until reaching 70% to 80% confluency. Then, the cells were harvested, and
chromatin was isolated and sheared according to the protocol of the Active Motif ChIPIT Express kit (#53008). For each ChIP reaction, 25 g of isolated chromatin was used
with 5 g of BRD4 antibody (#A700-004; Bethyl Laboratories) or normal rabbit
immunoglobulin G (IgG) (#2729S; Cell Signaling Technology) and incubated with ChIPIT Protein G Magnetic Beads (Active Motif) overnight with light agitation at 4C. The
next day, the beads were washed, and chromatin was eluted. The eluted chromatin
was processed according to the manufacturer’s protocol to eliminate any chromosomal
protein from genomic DNA and was used for ChIP PCR reactions. See primers used in
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Table 3-1. For regular PCR reactions, we used the AccuPrime GC-Rich DNA
Polymerase kit (#12337016; Thermo Fisher Scientific). The following thermocycler
(Eppendorf vapo.protect Mastercycler) conditions were used: 94C for 2 minutes of
initial denaturing, then 36 cycles at 94C for 30 seconds, 60C for 30 seconds, and
72C for 30 seconds. PCR products were then loaded in a 2% agarose gel made with
1× TBE buffer (1.0 M Tris, 0.9 M boric acid, and 0.01 M ethylenediaminetetraacetic
acid; #15581-028; Invitrogen UltraPure) and run for 120 volts alongside a 100- to
3,000-bp DNA ladder (#DNAL-100BP; Phenix). The gel was stained with ethidium
bromide and imaged under ultraviolet light. For qPCR reactions, isolated DNA was
further purified using the Active Motif ChIP DNA Purification Kit (#58002), and qPCRs
were run using SYBR Green reagent using the Applied Biosystems 7500 Real-Time
PCR System. To calculate fold enrichment, the DNA amount of normal rabbit IgG was
used as a normalizing value.

RPPA and NetWalker analysis
OVCAR 4 and OVCAR 5 cells were cultured in either DMSO or 1 M CPI203 for
48 hours. Then, cells were harvested and lysed with radioimmunoprecipitation assay
buffer (RIPA) supplemented with phosphatase and protease inhibitors and diluted to a
concentration of 1.5 g/L, which was mixed with 4× sample buffer (40% glycerol, 8%
sodium dodecyl sulfate, and 0.25 M Tris, pH 6.8) with no bromophenol blue, to which mercaptoethanol was added in a 1:10 ratio before use. Samples were prepared in
biologic duplicates, and a total of 40 L of samples was submitted to the MD Anderson
RPPA Core Facility and run using a validated set of antibodies (80). Initial protein
expression analysis provided by the core was done using the R statistical software
package (http://cran.r-project.org). To create a NOTCH3 gene signature in our ovarian
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cancer samples and study changes in expression of those genes after CPI203
treatment, we used NetWalker analysis software (81). Changes in expression were
determined by means of normalized log2 of DMSO-treated cells compared with
CPI203-treated cells. The generation of the final network is described in the Results.
Statistical analysis
Statistical analyses of in vitro and in vivo experiments were done using
GraphPad Prism 7. To determine whether differences between two groups were
significant, we used a two-tailed Student t-test (equal variance) or one-way analysis of
variance (ANOVA) for multiple group comparisons. For these analyses, a p value <
0.05 was considered significant. Results are presented as the mean ± standard
deviation of the mean. To test for outliers in our in vivo experiments, we used ROUT
analysis provided by Graph Pad Prism 7 software package to identify for multiple
outliers present in each treatment group (Q = 1%). For survival curve comparison
analysis, we used the Log-rank (Mantel-Cox) test. For TCGA analysis, Spearman’s
rank correlation test was performed using 309 to evaluate the correlation between
expression levels of BRD4 and other genes of specified in Fig. S1. The same test was
applied to investigate the correlation between BRD4 gene expression and copy number
within 303 ovarian cancer patients. For these analysis, we chose a p value of 3 x 10 -4
as the cutoff to evaluate significant correlations.
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Construct
siRNAs
Forward (5′-3′)

Sequences
Reverse (5′-3′)

siControl
siBRD4 1

GCGACAGCUGGGCUGAAUA[dT][dT]
CUGAUUACUAUAAGAUCAU

UAUUCAGCCCAGCUGUCGC
AUGAUCUUAUAGUAAUCAG

siBRD4 2

CUGGAAUGCUCAGGAAUGU

ACAUUCCUGAGCAUUCCAG

qPCR
primers
BRD4
NOTCH3

Forward (5′-3′)

Reverse (5′-3′)

AGTCCAGCTCCTCTGACAGC
GCTCTGGAGCCAATGCCAAC

GATGGTGCTTCTTCTGCTCC
CAGTCTCGCCAGTACGGTCA

HES1

TCAACACGACACCGGATAAAC

GCCGCGAGCTATCTTTCTTCA

36B4

ATCAACGGGTACAAACAGAGTCCTG AAGGCAGATGGATCAGCCAAGAAG
ChIP PCR Reverse (5′-3′)
Reverse (5′-3′)
primers
NOTCH3
GAAGGAGGGAGGAGGGGA
TTGGGGGTTCTTGCACTC
MYC
CTTACAACACCCGAGCAAGGAC
GCTGCTGGTTTTCCACTACCC
NOTCH2

TGAGCCTTTGAAGCAGGAGGAG

shRNAs
shControll

Top oligo (5′-3′)
CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTG

shBRD4

CCGGCCTGGAGATGACATAGTCTTACTCGAGTAAGACTATGTCATCTCCAGGTTTTTG

CATCTTCTCGGTCGCCTCCTC
Bottom oligo (5′-3′)
AATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG
AATTCAAAAACCTGGAGATGACATAGTCTTACTCGAGTAAGACTATGTCATCTCCAGG

Table 3-1. siRNAs, qPCR primers, ChIP primers, and shRNA sequences used in
this study.
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RESULTS

TPT identifies BRD4 as a therapeutic avenue to target Notch3 in ovarian cancer
We first employed the TPT to identify promising, clinically relevant targeted
therapies at the phase I clinical trial stage that can be re-purposed for ovarian cancer.
Our analysis revealed BETis, which inhibit the bromodomain containing the protein
BRD4 and have shown promise in other tumor models, as a top candidate (43, 82, 83).
On the basis of these findings, we proceeded with an in silico validation of the TPT in
which we explored the role of BRD4 in ovarian cancer. Independently probing gene
expression data of TCGA and GTEx databases revealed that mRNA expression of
BRD4 is highly upregulated in ovarian cancer compared with that in normal ovarian
tissues (Figure 2-2A). In validation of this result, using patient data sets from the TCGA
independent of the TPT, we found that in ovarian cancer, an increase in BRD4 copy
number strongly correlated with increased BRD4 mRNA expression (Figure 3-1A).
TCGA analysis also revealed that increased BRD4 expression in ovarian cancer
correlated with a significant decrease in survival (Figure 2-2B, p < 0.02). Taken
together, these computational analyses results provided the initial justification to
investigate the biologic impact of BRD4 inhibition in pre-clinical ovarian cancer models.
A critical feature of the TPT is that it correlates expression of a target gene with
the expression of oncogenic proteins associated with the cancer of interest to reveal
potential novel functional relationships. The anti-tumor effect of BETis has been
attributed to downregulation of the expression of oncogenes such MYC, which cannot
be directly targeted (43, 44).
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Figure 3-1. TCGA correlation analysis of BRD4 expression in ovarian cancer. (A)
Correlation plot comparing BRD4 copy number alterations and mRNA gene expression
in ovarian cancer. **** p < 1 × 10-10. (B-F) Correlation between BRD4 and MYC (B),
NOTCH1 (C), NOTCH2 (D), NOTCH3 (E), and NOTCH4 (F) expression in ovarian
cancer patient tumor samples. * p < 0.0003, **** p < 1 × 10 -10. Spearman’s rank
correlation test was performed using 309 patient samples to evaluate the correlation
between expression levels of BRD4 and other genes of specified. For these analysis,
we chose a p value of 3 x 10-4 as the cutoff to evaluate significant correlations.

39

Thus, using our tool, we sought to identify novel downstream molecular targets that
could be impacted by BRD4 inhibition in ovarian cancer. Comparing BRD4 mRNA
levels with RPPA data on proteins in TPT, we determined that BRD4 levels strongly
correlate with expression of Notch3 (Figure 2-3). Notch3 has been shown to be highly
upregulated in ovarian cancer and correlates with increased proliferation, increased
chemo-resistance, and decreased survival but has proven difficult to target directly (5759, 84, 85). To investigate whether this correlation between BRD4 and Notch3
upregulation is exclusive to the Notch3 receptor, we probed the ovarian cancer TCGA
data set. Our analysis revealed that there is indeed a high correlation between Notch3
and BRD4 expression in ovarian cancer (Spearman coefficient, 0.5052; p < 2.2 × 10 -16)
(Figure 3-1E), but increased BRD4 expression did not significantly correlate with
expression of MYC (Spearman coefficient, 0.00067; p = 0.906728), NOTCH1
(Spearman coefficient, 0.1505; p = 0.004644) and NOTCH4 (Spearman coefficient,
0.1575; p = 0.003159) receptors (Figure 3-1B, 1C and 1F). We did observe a
significant correlation between BRD4 expression and the NOTCH2 receptor (Spearman
coefficient, 0.2237, p = 7.58 x 10-5) but the Spearman coefficient was not as high nor
the p value was not as small when compared to BRD4 and NOTCH3 (Spearman
coefficient, 0.5052; p < 2.2 × 10-16, Figure 3-1E and 1D).

BRD4 inhibition has a therapeutic effect in pre-clinical ovarian cancer models

Next, to biologically validate our in silico findings, we evaluated the therapeutic
effect of BRD4 inhibition in ovarian cancer in vitro. BETis have proven effective in other
tumor models, including multiple myeloma and NUT midline carcinoma, which
propelled the use of BETis in clinical trials (34, 43, 86).
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Figure 3-2. BETi treatments decreases cell viability in ovarian cancer cell lines.
(A) Standard curve qRT-PCR analysis of relative BRD4 mRNA levels in ovarian cancer
cell lines compared with human isolated primary fallopian tube epithelial cells (FTE 4).
Experiment done in 2 independent biological duplicates, **** p < 0.001. One way
ANOVA was used to test for significance. (B) BRD4 protein levels in ovarian cancer
cells relative to those of FTE 4. Experiment done in 2 independent biological
duplicates. (C and D) MTT viability assays of ovarian cancer cells treated for 72 hours
with BETi CPI203 or CN210, respectively. Experiment done in 3 independent biological
duplicates. (E and F) Colony formation assay of ovarian cancer cells treated for 10
days with BETi CPI203 or CN210, respectively. Experiment done in 3 independent
biological duplicates.
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We first tested BRD4 expression in a panel of well-established ovarian cancer cell
lines. All ovarian cancer cell lines tested had substantially higher BRD4 mRNA and
protein levels than did freshly isolated patient-derived primary fallopian tube epithelial
(FTE4) cells (Figure 3-2A and 2B). FTE4 cells were used as a control given the
growing evidence of fallopian tube epithelial cells being one etiological source for
ovarian epithelial cancer (31, 87). The over-expression of BRD4 in ovarian cancer cells
is also in accordance with our in silico results described in previous sections (Figure 22A and Figure 3-1A). Next, we tested cell viability using the clinically relevant BRD4
inhibitors CPI203 and CN210, a novel, un-characterized pan-BETi (88, 89). Like other
BETis, such as JQ1, these inhibitors bind directly to the BRD4 bromodomains and
block BRD4’s ability to interact with acetylated chromatin (Figure 2-1B) (35). Both 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and colony formation
assays using either compound showed a significant decrease in cell viability and
growth, in association with treatment (Figure 3-2C, D, E and F). To determine that
these effects were due to BRD4 inhibition, and not due to off-target effects of the
compounds, we used siRNA to reduce BRD4 levels and then carried out MTT assays
(Figures 3-3A and B). There was again a significant decrease in cell viability in MTT
assays upon BRD4 knockdown (Figure 3-3B).
We next aimed to identify the biologic mechanisms underlying this decrease in
cell viability. Ovarian cancer cells treated with either BRD4 inhibitor, compared with
those treated with vehicle, demonstrated a significant decrease in 5-ethynyl-2′deoxyuridine (EdU) incorporation in most of the cell lines tested, suggesting a decrease
in proliferation (Figure 3-4A and B).
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Figure 3-3. BRD4 knockdown reduces cell viability in ovarian cancer cell lines.
(A) Confirmation of BRD4 protein knockdown in ovarian cancer cell lines 72 hours after
siRNA transfection. Experiment conducted in 3 independent biological replicates (B)
MTT viability assay of ovarian cancer cells transfected with BRD4 siRNA, 96 hours post
transfections. Experiment conducted in 3 independent biological replicates.
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Figure 3-4. BETi treatment decreases cell proliferation and increases apoptosis
in ovarian cancer cell lines. (A and B) EdU flow cytometry analysis of ovarian cancer
cells treated with BETi CPI203 or CN210, respectively, for 72 hours. * p < 0.05, ** p <
0.01, *** p < 0.001, ns (non-significant). (I and J) Annexin V flow cytometry analysis of
ovarian cancer cells treated with BETi CPI203 or CN210, respectively, for 72 hours. * p
< 0.05, ** p < 0.01, *** p < 0.001, ns (non-significant). All experiment done in 3
independent biological duplicates. Statistical significance was determined by
conducting unpaired Student t-test comparing vehicle control versus BETi treatments.
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Figure 3-5. BRD4 knockdown decreases cell proliferation and increases
apoptosis in ovarian cancer cell lines. (A) EdU incorporation 96 hours after BRD4
siRNA transfection, * p < 0.01. (B) Annexin V staining of ovarian cancer cells 96 hours
after BRD4 siRNA transfection. * p < 0.05, ** p < 0.01. Statistical analysis was done by
applying unpaired Student t-test for mean change in siControl group compared to either
siBRD4 1 or siBRD4 2. All experiment conducted in 3 independent biological replicates.
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Furthermore, we observed a significant increase in apoptosis upon treatment with
either inhibitor (Figure 3-4C and D). We observed similar results upon siRNA
knockdown of BRD4 (Figure 3-5A and B). These results show that BRD4 inhibition
has a positive therapeutic effect in pre-clinical ovarian cancer models and provide a
biologic basis for our TPT.

BRD4 inhibition decreases tumor growth and prolongs survival
On the basis of our in vitro results, we next aimed to investigate the anti-tumor
and survival effects of BRD4 inhibition in vivo. We first asked whether targeting BRD4
using CPI203, which showed a more potent inhibitory effect than CN210 did in vitro,
inhibits tumor growth in an OVCAR 5 orthotopic (intra-peritoneal) tumor model (90).
Tumor-bearing

mice

were

treated

daily

with

10

mg/kg

CPI203

(injected

intraperitoneally) for 21 days (Figure 3-6A). Compared with vehicle-treated mice,
CPI203-treated mice had significantly decreased tumor weights (p < 0.05; Figure 3-6B
and 3C) and non-significantly fewer tumor nodules (p = 0.0596; Figure 3-7A). To
identify the biologic mechanism by which BRD4 inhibition decreased tumor growth in
the OVCAR 5 tumor model, we performed immunohistochemical (IHC) staining on
tumor sections with either the proliferative marker Ki67 or the apoptosis marker cleaved
caspase-3. Tumors treated with CPI203 had a significant decrease in Ki67-positive
cells compared with vehicle-treated controls (Figure 3-6D and 3E). No significant
changes in cleaved Caspase-3 staining were observed between groups (Figure 3-7B
and C).
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Figure 3-6. BETi CPI203 decelerates OVCAR 5 tumor growth by decreasing
proliferation. (A) Schematic for CPI203 treatment in OVCAR 5 tumor-bearing mice.
(B) Tumor nodules (white arrows) in CPI203- or PBS-treated mice. (C) Mean tumor
weights in PBS (n = 8) and CPI203-treated mice (n = 6), * p < 0.05. Statistical
significance was determined using Student t-test for mean difference in tumor weights.
(D) IHC staining of OVCAR 5 tumors for Ki67. Scale bar, 100 m. N = 4 per group. (E)
Quantification of Ki67-positive cells from PBS- or CPI203-treated mice, n = 4 per group.
Quantification was done using pictures of five random fields from OVCAR 5 tumors.
Statistical significance was determined using Student t-test for mean difference in Ki67
positive cells.
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Figure 3-7. BETi treatment does not change number of tumor nodules or induce
apoptosis in the OVCAR 5 tumor model. (A) Total nodule count of OVCAR 5 tumorbearing mice treated with PBS vehicle control (n = 8) or CPI203 (n = 6). (B)

IHC

images of OVCAR 5 tumors harvested from mice and stained with cleaved caspase-3
(n = 5). Scale, 100 m. (C) Quantification of cleaved caspase–positive cells from either
PBS- or CPI203-treated mice (n = 5). Five random high-power fields from stained
tumors were used for quantification. Statistical analysis was done by applying unpaired
Student t-test for mean number of tumor nodules and mean number of positive cleaved
Caspase 3 tumor cells.
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To determine if these observations were unique to OVCAR 5 tumors, we conducted the
same experiment using a newly generated second ovarian cancer tumor model,
OVCAR 4ip1. Upon treatment with CPI203, we observed a significant decrease in both
tumor weights (Figure 3-8A and B, p < 0.05) as well as the number of tumor nodules
(Figure 3-8C, p < 0.05) in mice treated with CPI203 when compared to PBS treated
controls. Furthermore, CPI203 treated mice demonstrated a significant increase in
cleave Caspase-3 IHC staining (Figure 3-9A and B, p < 0.001) and a significant
decrease in IHC Ki67 staining (Figure 3-9C and D, p < 0.05). These results indicate
that decreased proliferation was the cause of decreased tumor growth in both OVCAR
5 and OVCAR4ip1 models as well as an increase in apoptosis in OVCAR 4ip1 model
alone, which are also consistent with our in vitro findings described above.
Next, we examined whether long-term BRD4 downregulation resulted in
increased survival, as predicted by the TPT. To do so, we generated a doxycyclineinducible shRNA system for luciferase-labeled OVCAR 5 cells, validated its function in
vitro, and injected the cells into nude mice (Figure 3-10A and B). Upon tumor
establishment, the mice were given a daily diet containing 200 mg/kg doxycycline to
induce BRD4 shRNA expression in tumor cells and were killed when moribund (Figure
3-11A) (91). Luciferase (IVIS) imaging revealed that induction of shBRD4 decreased
growth of tumors compared with induction of control shRNA, which is consistant with
BETi treatment (Figure 3-11B). To confirm that BRD4 was indeed being
downregulated in the OVCAR 5 tumors, we performed IHC. We observed that mice in
which we induced BRD4 shRNA, had a significant decrease in BRD4 expression when
compared to shBRD4 mice never exposed to doxycycline or mice expressing the nontargeting shRNA control sequence (Figure 3-12A and B).
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Figure 3-8. BETi treatment decreases tumor burden in OVCAR 4ip1 tumorbearing mice. (A) Tumor nodules in PBS vehicle control–treated mice (white arrows)
compared with CPI203-treated mice. (B) Quantification of total tumor weight per mouse
in each group, n = 8 per group, * p = 0.0172. Statistical analysis was done by applying
unpaired Student t-test comparing mean tumor weights between groups. (C)
Quantification of total tumor nodule counts per dissected mouse. n = 8 per group, * p =
0.0400. Statistical analysis was done by applying unpaired Student t-test comparing
mean tumor nodule counts between groups.
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Figure 3-9. BETi treatment decreases proliferation and increases apoptosis in
OVCAR 4ip1 tumor-bearing mice. (A) IHC staining of tumor nodules with cleaved
Caspase-3 (CC3) antibody. Scale bar, 50m (n = 5 per group). (B) Quantification of
CC3 IHC images. Five random high-power fields from stained tumors were used for
quantification. *** p < 0.001, statistical analysis was done by applying unpaired Student
t-test comparing mean number of cleaved Caspase3 positive cells between groups (n
=5 per group). (C) IHC staining of tumor nodules with Ki67 antibody. Scale bar, 50m.
(D) Quantification of Ki67 IHC images. Five random high-power fields from stained
tumors were used for quantification (n = 5 per group). * p < 0.05. Statistical analysis
was done by applying unpaired Student t-test comparing mean number of Ki67 positive
cells per group.
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Strikingly, mice with BRD4 knockdown had 50% increase in survival rate compared
with controls (Figure 3-12C; p < 0.001). These results are consistent with our in vitro
assays described above and provide further biologic support of the prediction given by
our algorithm.

BRD4 inhibition decreases Notch3 expression in ovarian cancer

We next tested whether there is a functional relationship between BRD4 and
Notch3 in ovarian cancer, as predicted by the TPT. Given not only the TPT prediction
but also BRD4’s known role as a transcriptional regulator, we hypothesized that BRD4
can directly regulate Notch3 expression in ovarian cancer (39, 40, 92). Treatment of
various ovarian cancer cell lines with BETi CPI203 or BETi CN210 produced a
decrease in Notch3 protein levels and mRNA levels (Figure 3-13). Notch3 protein and
mRNA levels were also decreased upon BRD4 knockdown using two different siRNA
sequences (Figure 3-14).
Next, we tested whether BRD4 knockdown downregulates Notch3 protein
expression in vivo using our OVCAR 5 tumor model. Treating tumor-bearing mice with
CN210 at 100 mg/kg resulted in decreased Notch3 staining on IHC analysis (Figure 315).

To

further

validate

these

results,

we

used

a

previously

described

dioleoylphosphatidylcholine (DOPC) liposomal particle delivery system to deliver BRD4
siRNA in OVCAR 5 tumors (79, 93). Tumor-bearing mice were injected intraperitoneally
with DOPC particles containing siBRD4 on days 1, 4 and 7 for a total of 3 treatments
every 3 days
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Figure 3-10. In vitro validation of doxycycline-inducible BRD4 shRNA system. (A)
qPCR 48 hours after adding doxycycline to OVCAR 5 cells. Experiment conducted in 3
independent biological replicates. *** p < 0.001. Statistical analysis was done by
applying one-way analysis of variance (ANOVA). (B) Verifying BRD4 expression 48
hours after exposure to doxycycline. Experiment done in 2 independent biological
replicates.
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Figure 3-11. BRD4 knockdown reduces tumor growth in vivo. (A) Timeline for
doxycycline-inducible shBRD4 survival experiment. (B) IVIS imaging of OVCAR 5
tumor-bearing mice 21 days after shRNA induction.
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Figure 3-12. BRD4 knockdown prolongs survival in ovarian cancer. (A) IHC
staining for BRD4 in OVCAR 5 tumor-bearing mice to confirm BRD4 knockdown in
vivo. Scale bar, 50 m. (B) Quantification of BRD4-positive cells from tumors in (H), **
p < 0.01, *** p < 0.001. Quantification was done using pictures of five random fields
from OVCAR 5 tumors and statistical significance was determined using Student t-test
for mean difference in BRD4 positive cells (n = 3 per indicated group). (C) Survival
curve of each indicated group after shBRD4 induction, *** p < 0.001. Comparison was
made to test for any significant difference between curves using Log-rank (Mantel-Cox)
test.
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On day 8 mice were euthanized and tumors were harvested for IHC. IHC analysis of
harvested tumors showed that upon BRD4 knockdown, there was a marked decrease
in Notch3 staining (Figure 3-16). These results are consistent with our in vitro findings
and suggest that BRD4 has a direct role in Notch3 transcription and promotes Notch3
mRNA expression in ovarian cancer.

BRD4 directly regulates NOTCH3 expression and impacts Notch3 downstream
targets

Given our results so far, we wanted to test whether BRD4 directly promotes
Notch3 transcription at the gene promoter level in ovarian cancer. Previous studies
suggest that BRD4 regulates expression of genes, including MYC, by recruitment to the
gene promoter (37, 44, 94). We performed chromatin immunoprecipitation (ChIP) of
BRD4 and conducted PCR using previously described primers that flank the
transcription start site of Notch3 (Figure 3-17A) (95). ChIP PCR demonstrated that
BRD4 was enriched at the Notch3 promoter in both cell lines tested (Figure 3-17B).
These results were quantified using qRT-PCR (Fig. 5C). BRD4 was also present at the
MYC transcription start site, as described in other tumor models (Figure 3-17C) (44).
Interestingly, BRD4 was not present at the NOTCH2 promoter, suggesting that BRD4
directly and preferentially regulates NOTCH3 gene expression in ovarian cancer
(Figure 3-17B). These results indicate that BRD4 directly promotes Notch3 expression
by enhancing its transcription at the gene promoter. Next, to understand the broader
downstream effects of BRD4 inhibition, we conducted reverse phase protein array
(RPPA) analysis in OVCAR 4 and OVCAR 5 cells that were treated with CPI203 for 48
hours.
56

Figure 3-13. BETi treatment decreases Notch3 expression levels in ovarian
cancer cells. (A and B) Protein expression analysis at 72 hours of full-length (FL) and
cleaved (C) Notch3 after BRD4 inhibition using the BETi’s indicated. (C and D) qRTPCR analysis of NOTCH3 mRNA expression 48 hours after BRD4 inhibition using
BETi. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). Statistical analysis was
done by applying unpaired Student t-test of mean fold change for vehicle control cells
compared to BETi treated cells. All experiments through have been repeated at least in
3 independent biological replicates.
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Figure 3-14. BRD4 knockdown decreases Notch3 expression levels in ovarian
cancer cells. (A) Protein expression analysis at 72 hours of full-length (FL) and
cleaved (C) Notch3 after BRD4 siRNA-mediated knockdown. (B) qRT-PCR analysis of
NOTCH3 mRNA levels after BRD4 siRNA-mediated knockdown (F). * p < 0.05, ** p <
0.01, *** p < 0.001, **** p < 0.0001, ns (non-significant). Statistical analysis was done
by applying unpaired Student t-test of mean fold change for vehicle control cells
compared to BETi treated cells. All experiments have been repeated at least in 3
independent biological replicates.
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Figure 3-15. BETi decrease Notch3 protein expression in vivo. IHC images of
OVCAR 5 tumors harvested from mice 24 hours after oral CN210 treatment at the
indicated doses. N = 3 for each indicted treatment group. Scale bar for 10x images,
200 m. Scale bar for 20x images, 100 m. Scale bar for 40x images, 50 m.
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Figure 3-16. BRD4 knockdown decreases Notch3 protein expression levels in
vivo. BRD4 (A) and Notch3 (B) IHC staining of OVCAR 5 tumors after Control (n = 5)
or BRD4 (n = 5) siRNA delivery by DOPC nanoliposomes. Scale bar for 10x images,
200 m. Scale bar for 20x images, 100 m. Scale bar for 40x images, 50 m.
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RPPA allows for the rapid assessment of protein level changes in various cancer
relevant signaling pathways, including Notch signaling. Based on our RPPA results, we
generated a NOTCH3 gene signature by combining previously identified Notch targets
in ovarian cancer as well as the Broad Institute NOTCH gene signature to determine
how protein levels of those targets would change in our RPPA data set after treatment
with CPI203 compared with vehicle (57). The results showed that OVCAR 4 cells had
an overall decrease in levels of Notch3 targets, including the previously described
target Hes1 (Figure 3-18) (57). In OVCAR 5 cells, these changes were less prominent,
but we also observed a downregulation of the Hes1 (Figure 3-19). We validated these
results using both Western blot as well as qPCR analysis and observed that after BETi
treatment, Hes1 protein (Figure 3-20A and B) and mRNA (Figure 3-20C) levels
decrease in both OVCAR 4 and OVCAR 5 cells after BETi treatment. These results
suggest that in ovarian cancer, BRD4 can directly regulate NOTCH3 transcription and
regulate NOTCH3 downstream gene targets in ovarian cancer. We further validated the
effect of BRD4 on HES1 transcription using siRNA and observed that upon BRD4
knockdown, there was also a significant decrease in HES1 transcription levels (Figure
3-21).
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Figure 3-17. BRD4 is enriched at the NOTCH3 gene promoter. (A) Schematic of the
NOTCH3 promoter and transcription start site. (B) Chromatin immunoprecipitation
(ChIP) PCR reactions after BRD4 pulldown at the indicated gene promoter regions.
Experiments repeated in 3 independent biological duplicates. (C) ChIP qPCR of
NOTCH3 transcription start site after BRD4 pulldown, * p < 0.05. Experiments repeated
in 3 independent biological duplicates. Statistical analysis was done by applying
unpaired Student t-test for mean fold enrichment of BRD4 over IgG control.

62

Figure 3-18. Defining Notch3 downstream targets impacted by BETi in OVCAR 4
cells. NOTCH3 gene signature generated from RPPA data using NetWalker software.
Fold change calculated based on NormLog2 expression difference of DMSO treated
cells versus CPI203 treated cells. Samples were submitted as 2 independent biological
duplicates.
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Figure 3-19. Defining Notch3 downstream targets impacted by BETi in OVCAR 5
cells. NOTCH3 gene signature generated from RPPA data using NetWalker software.
Fold change calculated based on NormLog2 expression difference of DMSO treated
cells versus CPI203 treated cells. Samples were submitted as 2 independent biological
duplicates.
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Figure 3-20. Downregulation of the Notch3 downstream target Hes1 after BETi
treatment in ovarian cancer cells. (A and B) Hes1 Western blot of cells treated with
BETi CPI203 (A) or CN210 (B). Experiments repeated in 2 independent biological
duplicates (C) qRT-PCR analysis of HES1 after BETi treatment. * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001. Experiments repeated in 3 independent biological
duplicates. Statistical analysis was done by applying unpaired Student t-test of mean
fold change for vehicle control cells compared to BETi treated cells.
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Figure 3-21. BRD4 knockdown decreases HES1 mRNA levels in ovarian cancer
cell lines. qRT-PCR analysis after BRD4 siRNA mediated knockdown (A) of HES1
mRNA transcript levels (B). * p < 0.05, ** p < 0.01, **** p < 0.0001. Experiments
repeated in 3 independent biological duplicates. Statistical analysis was done by
applying unpaired Student t-test of mean fold change for siControl cells compared to
siBRD4 knockdown treated cells.
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SUMMARY

In this study, we took a multidisciplinary approach to identify and re-purpose
clinically relevant targeted therapies. Our observations led us to characterize a novel
molecular relationship between BRD4 and Notch3 in ovarian cancer. Using our TPT,
we successfully predicted that early-stage BETis would provide significant therapeutic
and survival benefits in pre-clinical ovarian cancer models. Furthermore, we uncovered
BRD4’s ability to regulate Notch3 expression both in vitro and in vivo in ovarian cancer
models (Figure 3-22).
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Figure 3-22. Working model. (A) BRD4 promotes NOTCH3 transcription and
promotes ovarian cancer growth and progression. (B) BETi’s inhibits ovarian cancer
growth and decreases transcription of the BRD4 oncogenic target, NOTCH3.
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CHAPTER IV
DISCUSSION AND FUTURE DIRECTIONS
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DISCUSSION

Targeted cancer therapies and the TPT

The rise and development of targeted therapies has greatly impacted the
perspective of basic and translational researchers, up to clinicians running multicenter
clinical trials in how to approach cancer therapy (2). The ramifications of meticulous
and rigorous pre-clinical studies that characterize the molecular mechanisms and
genetic alterations which drive the growth and progression of specific cancer types can
directly impact patient treatment options and outcomes. The fruits of these efforts have
resulted in therapies that can range from small molecule inhibitors such as BETis and
PARPi, to antibody therapies like bevacizumab, all of which target specific molecules
(5, 12, 34). Furthermore, recent therapies are also designed to train the body’s own
immune system to attack tumor cells (96). With all these options, researchers and
clinicians can put together an arsenal that targets both tumor cells themselves as well
as their protective micro-environment. In spite of these advancements, due to the
rapidly evolving nature of cancer cells, tumors can gain resistance to these promising
therapeutics and fail to significantly improve patient outcomes for which they were
designed for (3, 15, 16, 96).
Instead of discarding these therapies, researchers are turning to readily
available and ever expanding bioinformatics databases (see Chapter I) to mine them in
order to identify molecular and/or genetic signatures in specific cancer types which
could be targeted by readily available targeted therapies (17). Even with these
resources, determining an effective way to easily compile and centralize the breadth of
information found in these databases to re-purpose targeted therapies remains
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challenging (17). It is this need that propelled us to generate our Therapy Predicting
Tool.
The design of the TPT is not the first of its kind. As described in Chapter
I, other research groups have tried to compile the information various databases in
order to generated predictive therapy response computational algorithms that have
yielded promising results (17, 24-27, 97, 98). Our tool is different in critical ways. First,
the TPT utilizes both TCGA and GTEx databases to generate its predictions for
potential gene targets, which allows compared expression changes from patient tumor
samples with normal tissue counterparts. This allows for more precise identification of
targets that are potential drivers of tumor growth and less likely to be background noise
inherent of large databases. Second, the TPT pairs the identified gene targets with
phase I clinical trial targeted therapies. This aids in speeding up the use of these
therapies in a clinical trial setting if pre-clinical studies demonstrate that the repurposed therapy yields a therapeutic effect in the tumor of interest. Lastly, the TPT
predicts potentially new downstream targets of the re-purposed targeted therapy in the
tumor type of interest, providing further rational for using the re-purposed targeted
therapy in the tumor of interest.
Based on the results presented in Chapter III, I was able to provide
biological evidence which validates the accuracy of the TPT. Not only did BETis
provide a beneficial therapeutic and survival effect, but it also uncovered a new
molecular relationship between Notch3 and BRD4 in ovarian cancer. Although the
results are highly encouraging, there also limitations to consider for the application of
the TPT. Just like other computational algorithms before it, it is dependent on the
accuracy of the original data sources such as TCGA and GTEx. This means that the
accuracy of the TPT can be influenced by any error in the original data collection to
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generate these databases and if the database is updated. Based on our biological
results, the data set and correlations were robust enough to predict a significant anticancer effect of BETis in ovarian cancer. Furthermore, if any significant updates are
made to the databases, we can simply incorporate those updated data sets in the TPT
to ensure precision and accuracy of its predictions. Another consideration that applies
to all computational approaches is that, regardless of what re-purposed therapy and
target combination the TPT produces for the cancer of interest, the pre-clinical model
systems may not respond as well as the TPT prediction (99, 100). Even within the
standard ovarian cancer cell lines used, there was some variability in the response to
the BETis used, both in vitro and in vivo (Figures: 3-2, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9) (90).
Thus, for future applications of the TPT, it is empirical that we test its effectiveness in
different cancer types before moving forward with it in a clinical setting.

Implication of BETi usage in ovarian cancer

The study presented here highlights the potential of streamlining the process of
rapidly identifying promising therapies, validating them and moving them to the clinical
trial setting. From my work, I have determined that BETis are not only are a viable
therapeutic avenue but can downregulate NOTCH3 in ovarian cancer. Since their
development, BETis have shown to be effective in a variety of cancers including:
multiple myeloma, acute myelogenous leukemia, NUT midline carcinoma, pancreatic,
breast and prostate (43, 44, 53, 54, 82, 83). This has lead the way to the set-up of a
multitude of clinical trials (34).
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Recently, multiple groups have independently explored the use of BETis in
ovarian cancer (101-105). Consistent with these previous studies, BETis demonstrated
beneficial anti-tumor effect in multiple ovarian cancer in vitro and in vivo pre-clinical
models. Additionally, in my work I used a novel BETi, CN210, which is a prime
candidate to be used in clinical trials. This is critical, given that there are currently no
clinical trials designed for the BETi usage to specifically treat ovarian cancer. In most of
the previous literature cited, the BETi predominantly used is JQ1, which is not suited for
direct clinical use and can have some off-target effects (35). Furthermore, using the
doxycycline inducible shRNA system, I was able to directly test the hypothesis that
tumor intrinsic BRD4 downregulation not only slows down tumor growth but also
significantly improves survival (Figure 3-12). This observation suggests that the antitumor effect of BETis is achieved by inhibiting BRD4 function within tumors.

BRD4 downstream targets in ovarian cancer

BRD4 is known to play an important part in regulating cell transcription (34, 39,
47). Depending on the biological context, such as disease or normal development,
BRD4 may have a plethora of downstream transcriptional targets that can regulate
specific cell functions (46, 47, 50, 106, 107). Previously published work through the use
of BETis, have to identified novel BRD4 downstream transcriptional targets such as
FOXM1, MYCN and ALDH1A1 in ovarian cancer (101, 104, 105). Due to the initial
prediction of the TPT in the study presented here, we can add NOTCH3 to that list,
which is known to play a role in ovarian cancer progression and is prognostic marker
for worse survival outcomes (57, 108). However, due to BRD4’s impact on multiple
genes, its pro-tumorigenic effects are not exclusively due to promoting Notch3
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expression. Regardless, similar to the MYC studies done in hematological
malignancies, we can now consider in the future using BETis as means to target
Notch3 signaling in ovarian cancer (42-44, 108). This is particularly exciting given the
inherent difficulty of directly inhibiting Notch signaling in patients due to the high toxicity
of -secretase inhibitors (76, 84). In comparison, BETis are better tolerated by patients
in a clinical setting (34). In the work presented, we only focused on the effect of BETis
in the perspective of BRD4 and Notch3, but generating specific gene networks and
signatures encompassing all of these identified BRD4 downstream targets may hold
promise in further personalizing the use of BETis in ovarian cancer.
Similar to BRD4, Notch signaling can have a broad effect in the transcriptional
landscape of the cell and the physiological impact this can have is also biologically
context dependent (Figure 2-4) (60, 65, 109). In the case of Notch3, its role in
development is mostly attributed to the development of the mammalian arterial vascular
system by promoting differentiation of arterial smooth muscle (66, 110). In the context
of cancer, overexpression or constitutive activation of Notch3 signaling is shown to play
a role in the progression of acute lymphoblastic leukemia as well as lung, breast,
gallbladder and ovarian cancer (57, 62, 71-73, 111). One of the major challenges in
understanding the role of Notch3 signaling in disease and development is identifying
downstream targets. For ovarian cancer, this is of particular interest since identifying
these downstream gene targets could present a novel avenue for developing targeted
therapies (56, 57, 59). In the work presented here, by using RPPA and NetWalker
analysis software, I was able to create a NOTCH3 gene signature based on previously
identified Notch targets in ovarian cancer as well as the Broad Institute NOTCH gene
signature, that is impacted by the use of BETis (56, 57, 59). I biologically validated
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these results by observing downregulation of Hes1 upon BETi treatment (Figure 3-20),
but it remains to be determined what the overall impact of this network has in
understanding the role of Notch3 signaling in ovarian cancer progression.

FUTURE DIRECTIONS

Further applications and biological validation of the TPT

Despite the extensive biological validation carried out in Chapter III, further
biological testing has to be carried before the use of the TPT can be implemented in a
clinical and patient setting. This implies not only further testing in ovarian cancer, but
expanding the use of the TPT for other tumor types. To further evaluate the effect of
chronic downregulation of BRD4 in ovarian, I am conducting a second survival using
our doxycycline inducible system, described in Chapter III, using the OVCAR 4ip1
tumor model (Figure 4-1). Distinct to OVCAR 5, OVCAR 4 cells demonstrated more
sensitivity to BETis both in vitro and in vivo ( Figures 3-4, 3-5, 3-6, 3-7, 3-8 and 3-9).
This experiment is currently ongoing due to the much slower growth rate of OVCAR
4ip1 cells compared to OVCAR 5 cells in vivo (90). Preliminary results demonstrate a
decrease in tumor growth in mice with active expression of BRD4 shRNA when
compared to mice expressing either shControl or shBRD4 mice never exposed to DoxChow (Figure 4-1B) (91). These results are consistent with the OVCAR 5 tumor model
(Figure 3-11).
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Figure 4-1. Testing the impact of survival of BRD4 knockdown in OVCAR4 ip1
tumor model. (A) In vitro validation of our doxycycline inducible shRNA system in
OVCAR4 ip1 cells by Western blot. Cells were exposed to 100ng/mL of doxycycline
and harvested to verify protein knockdown 48 hours later. (B) IVIS imaging of OVCAR
4ip1 tumor bearing mice, with indicated cell lines injected IP. IVIS imaging was
conducted on day 59 after introduction of Dox-Chow and induction of shRNA constructs
in tumor cells.
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If we observed a similar increase in survival, as we did with OVCAR 5 (Figure 3-12C),
after chronic tumor intrinsic BRD4 downregulation, this further strengthens the
predictions of the TPT and prompt the use of BETis in ovarian cancer patients.
The goal of the TPT is to expand its use to a multitude of tumor types. To
accomplish this, we need to ensure its biological accuracy in the tumor model of
interest. To start addressing this, I chose another gynecological tumor model,
endometrial cancer. Similar to ovarian cancer, patients that present with advance or
recurrent disease do not respond as well to standard chemotherapies (112). The TPT
predicted that BETis would provide a beneficial survival effect on endometrial cancer
that trended towards significance (p = 0.0618, Figure 4-2A). One possible explanation
for this result not being significant is because the TPT did not distinguish between the
different subtypes of endometrial cancer, which have different clinical characteristics
(112). We proceeded to test the effect of the BETi CPI203 and CN210 in two commonly
used endometrial cancer cell lines: Hec1-b and Ishikawa (113). Results demonstrated
that in both cell lines, BETis reduced cell viability by both colony formation and MTT
assays (Figure 4-2B-E). These results are also consistent with recently published work
using the BETi, JQ1 (48). I next used the TPT, to identify potentially novel downstream
targets of BRD4 in endometrial cancer. The top prediction that emerged was Cyclin B1,
which when upregulated is a marker for worse prognosis in endometrial cancer (114).
Additionally, expression of Cyclin B1 increases during G2/M transition during the cell
cycle, which is also a period where BRD4 is highly transcriptionally active (114-117).
Treatment of endomentrial cancer cells with BETis, resulted in a decrease in Cyclin B1
mRNA expression in both cell lines tested (Figure 4-3). Taken together, the results in
Figures 4-2 and 4-3 suggests that the accuracy of the TPT can extend beyond ovarian
cancer and merits future tests of drug/target combinations in other tumor types.
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Figure 4-2. BETi inhibition produces beneficial therapeutic effect in endometrial
cancer cell lines. (A) Survival curve based on TPT results showing a beneficial
survival benefit of BETis in endometrial cancer, which trends to significance. (B and C)
Colony formation assay of Hec1-b and Ishikawa cells treated with either CPI203 or
CN210. (D and E) MTT viability assays for Hec1-b and Ishikawa cells after treatment
with BETis CPI203 (D) or CN210 (E). All experiments from (B) to (E) have been done
in 3 biological triplicates.
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Figure 4-3. Targeting of BRD4 with BETis downregulates Cyclin B1 in
endometrial cancer cell lines. (A and B) qRT-PCR analysis of CCB1 gene
expression after treating with different concentrations of the BETis CPI203 (A) and
CN210 (B) in Hec1-b and Ishikawa cells. Experiments were conducted in 3
independent biological replicates. * p < 0.05, ** p < 0.01, *** p < 0.001 and ns = not
significant. Students t test was applied for determining statistical significance between
fold change of BETi treated cells compared to DMSO vehicle controls.
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Expanding the therapeutic potential of BETis in ovarian cancer

Ovarian cancer, particularly HGSC, is an extremely genetically complex disease
(9). Due to this genomic instability, acquired drug resistance is quite common, even to
promising targeted therapies (9, 15, 16). An alternative strategy to maximize the use of
targeted therapies, is to incorporate them in combination with either conventional
chemotherapies or with other targeted therapies (1, 3). The goal of this strategy is to
identify combinations that produce synergistic effect and more effective killing of cancer
cells.
In this study, we observed that as a monotherapy, BETi decreased tumor
growth in vivo, but did not completely abolish tumor growth. In the setting of clinical
trials for other tumor types, similar responses are observed in patients that are being
treated with BETis as a monotherapy (34). Thus, understanding the adaptive changes
that occur in a cell after BETi exposure may shed insight as to which patients will be
the best responders to BETis and on what combination of therapies would be effective
to shut down resistance inducing pathways. One modality that aids in identifying those
adaptive changes is RPPA. We conducted RPPA analysis on cells treated with BETi to
identify changes in downstream Notch3 proteins but the information provided by our
RPPA data set can go further beyond than just the restriction of one cell signaling
pathway (80). RPPA allows for the quantitative analysis of multiple proteins, as well as
protein modifications such as phosphorylation and cleavage, that are central for a
variety of major cancer related pathways (80). For the purpose of this study, RPPA
provided in sight of major signaling pathways whose activity changed before and after
BETi treatment. Using NetWalker network analysis software, I was able to determine
which cellular processes were significantly changed after BRD4 inhibition (81). In
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OVCAR 4 cells, which demonstrated higher sensitivity to BETis, BETi treatment
decreased expression in proteins involved in cell cycle progression and transcriptional
networks related to TP53, MYC and FOXM1 signaling, which has been previously
described in other ovarian cancer cell lines (38, 101, 105) (Table 4-1). Conversely,
there was an increase in proteins related to Insulin and mTOR signaling, which are
related to metabolism, stress responses and associated with chemotherapy resistance
in ovarian cancer (118) (Table 4-1). This suggests that in cells whereby BETi impacts
proliferative capacity are more likely to respond better to BETis. Interestingly, for
OVCAR 5, the more resistant cell line, there was an increase in proteins related to
immune cell as well insulin signaling and a downregulation in proteins involved in
overall tyrosine phosphorylation, leukocyte differentiation and cell adherens junctions
(Table 4-2). A recent report suggests that in ovarian cancer, re-programing of the
kinome may be responsible for acquired BETi resistance (103). One way to explore this
hypothesis is to create ovarian cancer patient derived xenograph (PDX) models, treat
them with BETis and run RPPA analysis on those tumors to observe if there are
changes in mTOR signaling (119). This could be incorporated back to clinical care and
decide if freshly resected tumors have high levels of BRD4 and Notch3, then adding
mTOR pathway inhibitors would be highly beneficial as well.
Other groups have started to explore the idea of combination therapies in
ovarian cancer that involve BETi (102, 120-122). Some of these reports have shown
promising combination strategies with PARPi and BETis, due to the ability of BETis to
stall the cell cycle (120, 121). It is yet to be determined whether these results are
consistent using our novel and clinically ready BETi, CN210.
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OVCAR 4 Upregulated Functional
Pathways
mTOR Signaling Pathway

Hypergeometric p Value

Insulin Receptor Signaling Pathway

4.84 x 10-9

B Cell Receptor Signaling Pathway

1.06 x 10-9

PI3K Cascade

1.38 x 10-9

Cellular Response to Insulin Stimulus

2.74 x 10-9

OVCAR 4 Downregulated Functional
Pathways
TP53 Network
FOXM1 Transcription Factor Network

Hypergeometric p Value

Cyclin A/B1 Associated Events During
G2/M Transition

2.10 x 10-12

regulation of chromosome organization

1.33 x 10-10

Validated Targets of C-MYC
Transcriptional Activation

1.68 x 10-10

2.51 x 10-10

9.29 x 10-13
1.82 x 10-12

Table 4-1. NetWalker analysis of functional pathways changes in OVCAR 4 cells
after BETi treatment.
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OVCAR 5 Upregulated Functional
Pathways
Acute Myeloid Leukemia

Hypergeometric p Value

Insulin Signaling Pathway

2.06 x 10-11

G1 to S Cell Cycle Control

2.51 x 10-11

B Cell Receptor Signaling Pathway

6.00 x 10-11

Apoptosis
OVCAR 5 Downregulated Functional
Pathways
Regulation of Peptidyl-Tyrosine
Phosphorylation

7.94 x 10-11
Hypergeometric p Value

EGFR1 Signaling Pathway

2.15 x 10-10

IL-3 Signaling Pathway

4.27 x 10-10

Leukocyte Differentiation

1.80 x 10-8

Adherens Junction

2.31 x 10-8

6.17 x 10-14

1.47 x 10-11

Table 4-2. NetWalker analysis of functional pathways changes in OVCAR 5 cells
after BETi treatment.
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Furthermore, it would be beneficial to pursue combinations with mTOR pathway
inhibitors or even drugs that can mitigate insulin signaling (123). Lastly, it would be
beneficial to further characterize CN210 and whether this would create synergistic
effect with immune checkpoint blockers, such as PDL-1, given the changes observed in
immune related proteins in OVCAR 5 (122).

Further Exploring the Functional Relationship between BRD4 and Notch3 in
Ovarian Cancer

In this study, I uncovered a novel functional relationship between BRD4 and
Notch3 in ovarian cancer. Specifically, the ability of BRD4 to promote NOTCH3
transcription by being enriched at the NOTCH3 promoter (Figure 3-22). BRD4 is
known to also regulate gene expression at enhancer sequences in association with the
Mediator complex (Figure 2-1) (46, 83). A past report identified the presence of
chromatin marks consistent with enhancer sequences within the NOTCH3 gene body
(110). To identify if BRD4 is present at these or other potential enhancer sequences for
NOTCH3, I would conduct a ChIP sequencing assay. This would be give us more
insight as to how BRD4 can directly regulate the expression of NOTCH3, as well as
other gene targets, in ovarian cancer.
It still remains to be determined how much of BRD4’s pro-tumorigenic effect in
ovarian cancer is mediated by promoting Notch3 over-expression. To determine this, I
attempted a rescue experiment where I stably over-expressed the cleaved, and
transcriptionally active, Notch3 intracellular domain (NICD3) using a lentiviral vector.
The rationale of this approach was that the expression of this active form of Notch3
does not depend on the presence or absence of BRD4 (Figure 4-4A). NICD3 over-
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expression was able to increase mRNA expression of HES1 (Figure 4-4B) but did not
alter basal expression of BRD4 in the ovarian cancer cells tested (Figure 4-4A).
Interestingly, when exposing these cells to the BETi CPI203, we observed that cells
became more responsive to CPI203 when compared to their parental counter parts
(Figure 4-4C and D). This effect may be in part due to off target effects produced by
excessively high levels of NICD3. Additionally, it has been reported that over activation
of Notch3 can also induce cell senescence (124). Several alternative approaches may
be taken to rule out the potential toxic effect of constitutive NICD3. First, I could
generate a doxycycline inducible NICD3 system to better control NICD3 expression
levels during the rescue experiments. Another approach is to use a DNA construct with
a much weaker promoter than pGK, such as the Ubiquitin C promoter to drive NICD3
expression and achieve more physiological expression levels (124). Lastly, another
alternative to these rescue experiments, would be to express a Notch3 downstream
gene target such as HES1 and attempt the rescue experiments both in vitro and in vivo.
Another aspect to consider when trying to understand the regulation of Notch3
expression in ovarian cancer is the possibility that other entities, including micro RNAs
(miR), may be independent of BRD4. A recent publication demonstrated that miR-150
can directly target Notch3 in ovarian cancer and increase sensitivity to paclitaxel (125).
It would be of interesting to explore what occurs to levels of miR-150 after inhibition or
knockdown of BRD4. Specifically, if miR-150 levels decrease after BETi treatment as a
means of compensating for decrease of NOTCH3 expression.
A second regulatory factor that may be impacting Notch3 expression in ovarian
cancer is the protein CTCFL, which is a paralog of CCCTC-binding factor (CTCF) (95).
In T-cell acute lymphoblastic leukemia, CTCFL was observed to occupy the NOTCH3
promoter and promote its transcription (95).
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Figure 4-4. Over expression of Notch3 intracellular domain and response to BETi.
(A) Western blot confirmation of lentiviral over-expression of the Notch3 intra-cellular
domain (NICD3) with a V5 protein tag. (B) qRT-PCR for HES1 expression after stable
NICD3-V5 over-expression. * p < 0.05, ** p < 0.01. Experiment done in 3 biological
replicates. Significance determined by Student t test. (C and D) MTT viability assay for
OVCAR 4 and OVCAR 5 parental and NICD3-V5 over-expressing cells after treatment
with CPI203.
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Furthermore, analysis of the cBioportal TCGA data set for ovarian cancer demonstrates
that CTCFL is amplified in a subset of ovarian cancer patients, alongside BRD4 and
NOTCH3 (Figure 4-5) (19). Whether CTCFL regulates expression of Notch3 in ovarian
and/or if BRD4 can recruit CTCFL to the NOTCH3 promoter or vice versa, remains
unknown. An initial experiment to start addressing this question would be to determine
if gain or loss of CTCFL expression alter NOTCH3 expression in ovarian cancer cells.
Additionally, I would investigate if CTCFL expression levels change in response to BETi
treatment. Lastly, I would determine whether CTCFL and BRD4 proteins interact with
each other by conducting co-immunoprecipitation experiments.
The exact role of Notch3 and BRD4 regulation in ovarian cancer development is
still not fully understood. BRD4 whole body knockout mice results in embryonic lethality
(46, 66, 126). Notch3 mediates development of the vascular system and recent studies
have shown the ability of BRD4 to induce expression of genes necessary for
myogenesis, the development of muscle, and adipogenesis, the development of
adipose tissue (46, 66). Little is known the role of these molecules in the development
of the normal ovary. By understanding the gene networks that these molecules could
regulate in development, this may shed more insight as to how those same gene
networks play a role in ovarian cancer. A previous study has demonstrated that in the
development of the mouse ovary, Notch3 mRNA is expressed in the granulosa cells
(producers of sex hormones) of the ovarian follicle as well as the corpus luteum, but not
in the oocyte itself (127).

BRD4 on the other hand, has been reported to promote

expression of the estrogen receptor in estrogen receptor positive cancers (128). This is
particularly interesting because the use of oral contraceptives is regarded as a potential
protective factor against ovarian cancer (9). The potential interplay between Notch3
and BRD4 in regulating hormone production and how this may impact both normal
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Figure 4-5. cBioportal oncoprint comparing expression of CTCFL and NOTCH3 in
ovarian cancer. Oncoprint was generated and altered from the cBioportal tool
(cbioportal.org) (19). To generate oncoprint, I first accessed the cbioportal home page
and then I chose the TCGA data set available for ovarian cancer and input the genes
BRD4, NOTCH3 and CTCFL in the gene entry box in order to compare genomic
alterations found for these 3 genes in ovarian cancer. The oncoprint generate
summarizes the results of the analysis, demonstrating what percent of patients in the
dataset have alterations in each of the genes of interest.
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development and ovarian cancer initiation and progression remains completely
unknown. Despite this ambitious approach, exploring avenues to generate conditional
knock out and knock in mouse ovary for BRD4 and Notch3 would start providing
answers to these questions.

Clinical Relevance and Implications of the TPT

The use of the TPT opens a potential new door for clinicians. After further and
extensive biological validation, the TPT could be easily applied in a clinical trial setting,
particularly in the initial trial design. The TPT can systematically predict, biologically
relevant targeted therapies which can be easily re-purposed and given in a novel
combination with either standard chemotherapies or other FDA approved targeted
therapies for the cancer of interest. By taking this approach, clinicians can help
maximize the success of the trial and improve patient outcomes. This may be
specifically relevant if the tool identifies a therapy that targets multiple downstream
genes associated with poor survival in a specific tumor type. Another application for the
TPT may be its use when having to take an adaptive clinical trial approach (129). In the
unfortunate circumstance that a phase II or phase III clinical trial might not be
producing the expected results, the TPT may aid in identifying new treatment arms to
be added as an amendment to the trial instead of having to start all over again.
In the context of the results described in Chapter III, I demonstrated the antitumor effect provided by BETis in ovarian cancer pre-clinical models, based on the
TPT’s prediction. Based on this, we could incorporate the use of BETIs, such as
CN210, and design a clinical trial to give in distinct combinations with platinum, taxol,
PARPi or bevacizumab therapies (9). The use of BETis might be particularly useful in
89

the treatment of recurrent or advanced high grade serous ovarian cancer patients, as
these cases not only have worse outcomes, but high a higher propensity for chemoresistance (9).

These applications demonstrate how the TPT and its ability to re-

purpose targeted therapies may directly impact the future of cancer patient care.
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